Aerosol analogs and methods of making and using same

By modifying the 7-position of aspartic acid and 7-position of cymenecin, OCF-I, OCF-J, OCF-M and OCF-N analogs were prepared, which solved the problem of insufficient activity of cymenecin in treating systemic fungal infections and anticancer in animal model systems, and achieved more efficient infection treatment and targeted delivery.

CN121311495APending Publication Date: 2026-01-09TEXAS A&M UNIVERSITY +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202480015882.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-02-03
Filing Date
2024-02-02
Publication Date
2026-01-09

AI Technical Summary

Technical Problem

Existing cytomegaloxins are ineffective in treating systemic fungal infections in animal model systems and show high serum protein binding, and their anticancer properties and antiparasitic activities need to be improved.

Method used

By modifying the 7-position of aspartic acid and the 7-position of cytosine, OCF-I, OCF-J, OCF-M and OCF-N analogs were prepared. These analogs were then selectively modified by carbodiimide-mediated amidation to form semi-synthetic analogs, which enhanced their antifungal and anticancer activities. Furthermore, they could be conjugated with linker monoclonal antibodies for targeted delivery.

Benefits of technology

It enhances the antifungal and anticancer activity of cytomegalocin analogues, provides a more effective treatment for systemic infections, and enables targeted delivery to specific cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005572998830000091
    Figure BDA0005572998830000091
  • Figure BDA0005572998830000101
    Figure BDA0005572998830000101
  • Figure BDA0005572998830000131
    Figure BDA0005572998830000131
Patent Text Reader

Abstract

The subject disclosure relates to a method of synthesizing aerolite analogs using an aerolite variant containing aspartic acid (ASP7) or glutamic acid (GLU7) at position 7, replacing the previously characterized asparagine at position 7. Selective semi-synthetic analogs produced using the ASP7 and GLU7 variants exhibit improved antifungal activity as compared to the ASN7 aerotoxin variant. The ASP7 and GLU7 variants of aerotoxin and compositions thereof are useful for the treatment of fungal and parasitic infections as well as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 443,060, filed February 3, 2023, the disclosure of which is incorporated herein by reference in its entirety, including all figures, tables and amino acid or nucleic acid sequences.

[0003] Declaration of sequence list

[0004] The sequence list in this application, named "Seq-List.xml", was created on February 1, 2024, and is 32,956 bytes in size. The entire contents of the sequence list are incorporated herein by reference in their entirety.

[0005] Statement on Federally Funded Research

[0006] The completion of this invention was supported by the government under Project 2R42AI131792-02A1 granted by the National Institutes of Health (NIH). The government holds certain rights to this invention. Background Technology

[0007] Cyanobacterium is produced by soil bacteria contaminating Burkholderia contaminants MS141. 1 A fungal substance produced by cytokinin. Cytokinin is a cyclic glycopeptide produced via a non-ribosomal pathway, consisting of 8 amino acids (Figure 1).

[0008] The mechanism of action of cyprodin is presumed to involve disrupting the physiological and biological activity of actin. The bactericidal activity of cyprodin has been demonstrated in various fungal species, including multidrug-resistant Candida glabrata and Candida auris. 2 These results spurred the development of fentanyl as an antifungal agent for the treatment of vulvovaginal vulva (already demonstrated in mouse models). 2,3 Oral and dermal fungal infections. Zanthoxycycline showed no efficacy in in vivo treatment of systemic fungal infections in animal model systems, possibly due to the compound's strong binding to serum proteins in these systems. 3 .

[0009] Studies have shown that cytosine also exhibits chemotherapeutic activity against various cancer cell lines. Its anticancer properties are comparable to its antifungal activity. 4 It has stronger efficacy and minimal toxicity. Zanthoxycycline has also shown antiparasitic activity against the gastrointestinal parasite Cryptosporidium parvum in vitro. 5Therefore, there is still a need to produce analogues of fentanyl to provide optimized, novel variants that can be used to treat systemic fungal infections, as anticancer agents, or as antiparasitic agents. Summary of the Invention

[0010] This disclosure provides a method for producing novel scavengin analogs derived from scavengin variants, preferably aspartic acid 7 variants (OCF-I and OCF-J) and glutamate 7 variants (OCF-M and OCF-N). Variants OCF-I and OCF-J contain aspartic acid (ASP7) at position 7, while OCF-M and OCF-N contain glutamate (GLU7) at position 7, replacing asparagine (ASN7) present in previously isolated and identified scavengin variants (OCF-A and OCF-B). In some embodiments, the carboxylic acid functional group at position 7 can be selectively modified via a carbodiimide-mediated amidation reaction to produce semi-synthetic analogs.

[0011] In some embodiments, the various analogues of OCF-I, OCF-J, OCF-M, and OCF-N described herein possess antifungal activity. In some embodiments, cytosine variants derived from OCF-I, OCF-J, OCF-M, and OCF-N exhibit enhanced antifungal activity compared to ASP7 and GLU7 variants (e.g., OCF-I, OCF-J, OCF-M, and OCF-N). Therefore, certain embodiments of this subject matter disclosure provide methods for controlling fungal and parasitic infections by administering the OCF-I, OCF-J, OCF-M, and OCF-N analogues described herein to subjects in need.

[0012] In some embodiments, the ASP7 or GLU7 residues of OCF-I, OCF-J, OCF-M, and OCF-N analogs may be modified to include a linker arm for attaching a monoclonal antibody, thereby enabling a targeted delivery system for specific cancer cells. In some embodiments, the engineered conjugates at the ASP7 or GLU7 position may contain a variety of other selective functional groups, such as amino, aldehyde, alkynyl, or hydroxyl groups. Attached Figure Description

[0013] The patent or patent application document contains at least one drawing in color. The United States Patent and Trademark Office will provide a copy of the patent or patent application publication containing the color drawing upon request and payment of the necessary fees.

[0014] Figure 1A-1C The chemical structure of cytosine. Figure 1A The chemical structures of OCF-A, OCF-B, OCF-I, and OCF-J are shown, with numbers indicating the positions of amino acids. Figure 1BChemical structures of OCF-K, OCF-L, OCF-M, and OCF-N, with numbers indicating the positions of amino acids. Figure 1C Schematic diagram of amino acid arrangement. OCF-A and OCF-B have an asparagine residue at position 7. OCF-A (1200.59 Da) has an asparagine residue at position 1, while OCF-B (1216.59 Da) has β-hydroxyasparagine at position 1. These two variants cannot be separated by HPLC. OCF-I and OCF-J have an aspartic acid residue at position 7 and a hydrogen or hydroxyl group at position 1, respectively (R1). OCF-K and OCF-L have a glutamine residue at position 7. OCF-K has an asparagine residue at position 1, while OCF-L (1230.61 Da) has β-hydroxyasparagine at position 1. OCF-M and OCF-N have a glutamate residue at position 7. OCF-M has an asparagine residue at position 1, while OCF-N (1231.59 Da) has β-hydroxyasparagine at position 1.

[0015] Figure 2 Chromatogram of the extract contaminated with Burkholderia MS141 (B. contaminans MS14), using acetonitrile (ACN) and 10 mM triethylamine, both containing 0.1% formic acid (FA), as the mobile phase. The initial concentration of the 10 mM triethylamine 0.1% FA mobile phase was 90%, reduced to 20%, and held at 60% for 10 minutes. The sample was injected at 5 minutes of run, where a sharp drop in pressure served as an indicator. The absorbance of cytosine was monitored at 220 nm (amino acids) and 280 nm (aromatic amino acids). Since β-hydroxytyrosine 4 is the only aromatic amino acid, cytosine showed a higher absorbance at 220 nm than at 280 nm. Table 1 lists the variants eluted at the indicated peaks.

[0016] Figures 3A-3B Nuclear magnetic resonance (NMR) data. Figure 3A The TOCSY fingerprint region of the OCF-A / OCF-B and OCF-I / OCF-J mixtures is shown in the figure. The newly designated ASP7 spin system and another new spin system designated GLN7 are also shown. Other amino acids present in cytosine are also labeled in the figure. Orange lines indicate unknown spin systems. Figure 3B NOESY data show the NOE (nuclear Oferhauser effect) from Hα of GLY6 to HN of the ASP7 and ASN7 spin systems, indicating the presence of interactions. NOEs outside this region were also observed, suggesting interactions between Hα and Hβ of the ASN7 and ASP7 spin systems and HN of the SER8 spin system. Table 2 also lists the proton chemical shift assignments for each amino acid spin system and xylose.

[0017] Figures 4A-4B Nuclear magnetic resonance (NMR) data. Figure 4A The TOCSY fingerprint regions of OCF-S3 and OCF-S4 are shown. The spin system of ASP7 is no longer present, and a new spin system designated as N-methylamide 7 appears, indicating that OCF-I and OCF-J were completely converted in the EDC condensation reaction. Other amino acids present in succinate are also marked in the figure. Orange lines indicate unknown spin systems. Figure 4B NOESY data show the NOE between Hβ of N-methylamide 7 and γ-NH and amide methyl groups, indicating an interaction. Overlapping NOEs were observed, indicating an interaction between Hα of GLY6 and HN of the N-methylamide 7 spin system. NOEs were also observed outside this region, indicating an interaction between Hα and Hβ of the N-methylamide 7 spin system and HN of SER8. NOEs for other amino acids in serotonin have also been labeled. Table 3 also lists the proton chemical shift assignments for each amino acid spin system and xylose.

[0018] Figures 5A-5B It demonstrates ASP7 ( Figure 5A ) and GLU7 ( Figure 5B The diagram illustrates the condensation reaction of fentanyl with various amines. Ten molar equivalents of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 1-hydroxybenzotriazole (HOBt), and an amine were added to OCF-I, OCF-J, OCF-M, and OCF-N. The reaction was carried out in N,N-dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) and incubated at room temperature for at least 16 hours, followed by separation using reversed-phase high-performance liquid chromatography (RP-HPLC).

[0019] Figures 6A-6F Prodrug design for cytosine. Figure 6A EDC was used to condense OCF-I / OCF-J with a 3-amino-1-propanol analog containing a prodrug moiety attached to an alcohol linker arm. Figure 6B It contains a cytosine analogue with a prodrug moiety attached to an alcohol linker arm, which is metabolized by an enzyme to produce OCF-S19 / OCF-S20. Figure 6C OCF-S21 / OCF-S22 contains a phosphate group attached to the linker arm. After incubation with alkaline phosphatase, the phosphate group is removed to generate OCF-S19 / OCF-S20. Figure 6D EDC was used to condense OCF-M / OCF-N with a 3-amino-1-propanol analog containing a prodrug moiety attached to an alcohol linker arm. Figure 6EThe glutamate variant of cytosine analogue synthesized from OCF-M and OCF-N contains a prodrug moiety attached to an alcohol linker arm, which is metabolized by an enzyme to generate the glutamate variant OCF-S19 / OCF-S20. Figure 6F The glutamate variants OCF-S21 / OCF-S22 have a phosphate group attached to the linker arm. After incubation with alkaline phosphatase, the phosphate group is removed to generate the glutamate variants OCF-S19 / OCF-S20.

[0020] Figure 7 S. cerevisiae DGY6 coverage assay. Spot A) 5 μg OCF-S19 / OCF-S20. Spot B) 5 μl alkaline phosphatase reaction mixture (containing 0.5 μl rCutsmart buffer). TM (0.25 μl Quick CIP, 4.25 μl ddH2O). Spot C) 5 μl of alkaline phosphatase reaction mixture after incubation at 37 °C for 90 min. Spot D) 5 μg of OCF-S21 / OCF-S22. Spot E) 5 μg of OCF-S21 / OCF-S22 with alkaline phosphatase reaction mixture. Spot F) 5 μg of OCF-S21 / OCF-S22 with alkaline phosphatase reaction mixture after incubation at 37 °C for 90 min. Each spot volume was 5 μl for comparison. These experiments help to understand the effects of different compounds and their treatments on yeast growth.

[0021] Sequence Summary

[0022] SEQ ID NO:1: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asn7-Ser8].

[0023] SEQ ID NO:2: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asn7-Ser8].

[0024] SEQ ID NO:3: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-chloro-BHY4-DABA5-Gly6-Asn7-Ser8].

[0025] SEQ ID NO:4: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-chloro-BHY4-DABA5-Gly6-Asn7-Ser8].

[0026] SEQ ID NO:5: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6,7-trihydroxy-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asn7-Ser8].

[0027] SEQ ID NO:6: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6,7-trihydroxy-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asn7-Ser8].

[0028] SEQ ID NO:7: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6,7-trihydroxy-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asp7-Ser8].

[0029] SEQ ID NO:8: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6,7-trihydroxy-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asp7-Ser8].

[0030] SEQ ID NO:9: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asp7-Ser8].

[0031] SEQ ID NO:10: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Asp7-Ser8].

[0032] SEQ ID NO:11: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Gln7-Ser8].

[0033] SEQ ID NO:12: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Gln7-Ser8].

[0034] SEQ ID NO:13: Sequence of the cyclic cyclophosphamide antibiotic. [Asn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Glu7-Ser8].

[0035] SEQ ID NO:14: Sequence of the cyclic cyclophosphamide antibiotic. [β-hydroxyAsn1-3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid 2-Ser3-BHY4-DABA5-Gly6-Glu7-Ser8]. Detailed Implementation

[0036] The singular forms “a,” “an,” and “the” used herein are intended to include their plural forms unless the context clearly indicates otherwise. Where “comprising,” “including,” “having,” “containing,” “with,” or variations thereof are used in the detailed description and / or claims, these terms are intended to be inclusive, similar to the term “comprising.” The transitional terms / phrases (and any grammatical variations thereof) “comprising,” “comprises,” “comprise,” “consisting essentially of,” “consists essentially of,” “consisting,” and “consists” are used interchangeably.

[0037] The phrase “consisting essentially of” indicates that the described embodiments include embodiments containing the specified materials or steps, as well as those embodiments that do not substantially affect the essential and novel features of the described embodiments.

[0038] The term "about" refers to an acceptable range of error for a particular value as determined by a person skilled in the art, the range of which depends in part on the method of measurement or determination of the value, i.e., the limitations of the measurement system. In the context of polynucleotide length, when "about" is used, these polynucleotides contain the stated number of bases or base pairs, varying within 0-10% (X ± 10%) of that value. In the context of compositions containing component amounts, when "about" or "approximately" is used, these compositions contain the stated component amount, varying within 0-10% (X ± 10%) of that value.

[0039] In this disclosure, ranges are represented in abbreviated form to avoid a verbose listing and description of every value within the range. Any suitable value may be chosen from the range as the upper limit, lower limit, or endpoint of the range, where appropriate. For example, a range of 0.1–1.0 represents the endpoint values ​​0.1 and 1.0, as well as intermediate values ​​such as 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, etc., and all intermediate ranges contained within the 0.1–1.0 range, such as 0.2–0.5, 0.2–0.8, 0.7–1.0, etc. It is envisioned that values ​​within the range have at least two significant digits; for example, a range of 5–10 represents all values ​​between 5.0 and 10.0, and all values ​​between 5.00 and 10.00, including endpoint values.

[0040] When this document uses the term "range," such as for a dose range, specific implementations of combinations and sub-combinations of ranges within that range (e.g., sub-ranges within the disclosed range) are intended to be explicitly included.

[0041] "Pharmaceutical acceptable" means a substance that has been approved or is likely to be approved by a federal or state regulatory agency, or by an appropriate agency in a country other than the United States, or is listed in the United States Pharmacopeia or other generally recognized pharmacopoeia, and is suitable for use in animals, especially in humans.

[0042] "Pharmaceutical-acceptable salt" refers to the salt of the virgin virgin analog contained in this disclosure, which is pharmaceutically acceptable and possesses the pharmacological activity desired by the parent virgin virgin analog. Specifically, such salt can be non-toxic, can be an inorganic or organic acid addition salt, or can be a base addition salt.

[0043] "Pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient, or carrier administered with the cytosine analogues of this disclosure. "Pharmaceutically acceptable carrier" means a non-toxic, biologically tolerable, and generally suitable substance for administration to a subject, such as an inert substance added to a pharmaceutical composition or otherwise used to facilitate drug delivery, and that substance is compatible with the composition. Examples of carriers include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and starch types, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycol.

[0044] "Subjects" include humans or non-human animals, particularly mammals such as cattle, pigs, dogs, rodents, or felines.

[0045] In one embodiment, “treating” or “treatment” refers to improving an infection or cancer (i.e., preventing or reducing the development of the disease or at least one of its clinical symptoms). In another embodiment, “treating” or “treatment” refers to improving at least one physical parameter that may not be perceptible to the subject. In yet another embodiment, “treating” or “treatment” refers to modulating an infection physically (e.g., stabilization of perceptible symptoms), physiologically (e.g., stabilization of physical parameters), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of an infection.

[0046] As used herein, the terms “reduce,” “inhibit,” “block,” “prevent,” “mitigate,” or “alleviate”, when referring to quartan analogues, mean that, compared to the absence of the quartan analogue or a composition containing the quartan analogue, the quartan analogue reduces the incidence, severity, size, volume, or related symptoms of infection or cancer by at least about 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 100%.

[0047] In some embodiments, the methods of this disclosure include administering a therapeutically effective amount of a cytomegalovirus analog to a subject who has an infection or cancer, or who has been diagnosed with an infection or cancer. "Therapeutically effective amount" means an amount or dose sufficient to produce the desired therapeutic or preventative effect in a patient requiring such treatment.

[0048] The effective dose or dosage of the cytomegalovirus analogue disclosed herein can be determined by conventional methods, such as modeling, dose escalation studies, or clinical trials, taking into account conventional factors such as the method of administration or drug delivery, the pharmacokinetics of the cytomegalovirus analogue, the severity and duration of the infection, the subject's prior or ongoing treatment, the subject's health status and response to the drug, and the attending physician's judgment. An example dosage range is approximately 0.001 to approximately 200 mg of the cytomegalovirus analogue per kilogram of the subject's body weight per day, preferably approximately 0.05 to 100 mg / kg / day, or approximately 1 to 35 mg / kg / day, more preferably approximately 1, 5, 10, or 20 mg / kg / day, which can be administered as a single dose or in divided doses (e.g., twice daily, three times daily, or four times daily). For a 70 kg human, a suitable dosage range is, for example, approximately 0.05 to approximately 7 g / day, preferably approximately 0.07 to approximately 2.45 g / day, more preferably approximately 0.07, 0.35, 0.7, or 1.4 g / day.

[0049] The structures of natural analogues of cytosine are provided by formulas (IX) and (X): Formula (IX):

[0050]

[0051] Where R 1 For H or OH, R 2 It can be NH2 or OH.

[0052] Equation (X):

[0053]

[0054] Where R 1 For H or OH, R 2 It can be NH2 or OH.

[0055] As shown in formulas (IX) and (X), the natural analogues of cyproterone acetate consist of eight amino acids (SEQ ID NOs: 1-14), a C18 aliphatic amino acid containing xylose (hereinafter referred to as NAA), and 2,4-diaminobutyric acid (DABA) (NAA is 3-amino-5,6-dihydroxy-7-O-xylose-octadecanoic acid, located at position 2 in SEQ ID NOs: 1-4 and 9-14). The structural analogues of formulas (IX) and (X) differ in that an oxygen atom is added to asparagine 1 (Asn1) to form β-hydroxyasparagine 1 (BHN1), and an amino acid residue at position 7. For formula (IX), the cyproterone acetate analogues OCF-A (SEQ ID NO: 1) and OCF-B (SEQ ID NO: 2) have an asparagine residue at position 7. OCF-A (1200.59 Da) has an asparagine residue at position 1, while OCF-B (1216.59 Da) has β-hydroxyasparagine at position 1. OCF-I (SEQ ID NO:9) and OCF-J (SEQ ID NO:10) have an aspartic acid residue at position 7 and either a hydrogen or a hydroxyl group at position 1, respectively. For formula (X), OCF-K (SEQ ID NO:11) and OCF-L (SEQ ID NO:12) have a glutamine residue at position 7. OCF-K has an asparagine residue at position 1, while OCF-L (1230.61 Da) has β-hydroxyasparagine at position 1. OCF-M (SEQ ID NO:3) and OCF-N (SEQ ID NO:14) have a glutamic acid residue at position 7. OCF-M has an asparagine residue at position 1, while OCF-N (1231.59 Da) has β-hydroxyasparagine at position 1. The identity of the cymenecin analogues was confirmed by high-resolution mass spectrometry (HRMS) analysis (Table 4). Reversed-phase high-performance liquid chromatography (RP-HPLC) was used to separate the aspartic acid 7 variants (OCF-I and OCF-J) and glutamate variants (OCF-M and OCF-N) of cymenecin, enabling their separation from the previously characterized asparagine 7 variants (OCF-A and OCF-B) (Table 1). OCF-K and OCF-L were co-eluted with OCF-A and OCF-B in RP-HPLC, while OCF-M and OCF-N were co-eluted with OCF-I and OCF-J. Nuclear magnetic resonance (NMR) analysis confirmed that the 7th residue contained either aspartic acid or glutamate.

[0056] Some embodiments of this disclosure provide cytosolic acid analogs and methods for their preparation.

[0057] The OCF-I, OCF-J, OCF-M, and OCF-N variants provide novel sites for the production of analogs because the terminal side chains of ASP7 or GLU7 are the only carboxylic acids in the compound. The single carboxylic acid in the molecule provides a selective region that can be used to modify natural products via a variety of synthetic chemistry approaches. In some embodiments, the carboxylic acid at the 7th position has been selectively modified by forming an amide bond with various amines through a condensation reaction mediated by carbodiimides (e.g., EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N'-dicyclohexylcarbodiimide (DCC), or N,N'-diisopropylcarbodiimide (DIC)). Figure 5A (See Table 5). All semi-synthetic analogs were confirmed by mass spectrometry and nuclear magnetic resonance (NMR) analysis.

[0058] In some embodiments, the carbodiimide-mediated condensation reaction is a simple, highly selective one-step reaction that can be used for the high-throughput semi-synthetic production of analogs. This carbodiimide coupling reaction has been carried out on a carboxylic acid with a variety of primary and secondary amines on the side chain of ASP7 or GLU7. In some embodiments, the amine is ammonia, methylamine, dimethylamine, ethylamine, propylamine, butylamine, pentylamine, hexylamine, heptylamine, octylamine, nonylamine, decylamine, undecylamine, or dodecylamine, but-3-yn-1-amine, 3-amino-1-propanol, 3-aminopropyl-dihydrophosphate, an amine coupled to a prodrug functional group (e.g., a phosphate group, methyl or benzyl succinate) (e.g., 3-amino-1-propanol), or any primary or secondary amine having various alkyl and / or aryl groups. In some embodiments, 1-hydroxybenzotriazole (HOBt), 4-(dimethylamino)pyridine (DMAP), N-hydroxysulfosuccinimide (Sulfo-NHS), [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide (HATU), or any combination thereof, are added to the condensation reaction. In some embodiments, the condensation reaction is carried out in N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), methyl tert-butyl ether (TBME), cyclopentylmethyl ether (CPME), dichloromethane, dimethyl carbonate (DMC), ethyl acetate (EtOAc), or isopropanol (IPA). In some embodiments, a 10-fold molar excess of the desired amine, EDC, and 1-hydroxybenzotriazole (HOBt) is used relative to the cytosine analogue, for example, in DMF or DMSO at room temperature (e.g., from about 18°C ​​to about 25°C) for about 16, 18, 20, 22, 24, 26, 28, 30, 36, 48 hours or longer, preferably under light-protected conditions. In some embodiments, longer incubation times and / or incubation at about 35°C have shown greater efficiency for certain amines used in the reaction (especially larger amines).

[0059] In some embodiments, a cross-linking catalyst (e.g., N-hydroxysuccinimide) can be used to activate the carboxyl group, and the activated cytosine intermediate can be used in high-throughput combinatorial chemistry to rapidly generate a large number of analogue libraries.

[0060] In some embodiments, multi-component reactions (such as the Ugi reaction and the Passerini reaction) can be used to further chemically modify the ASP7 (OCF-I and OCF-J) or GLU7 (OCF-M and OCF-N) fluoridin variants containing carboxylic acid modification sites. In some embodiments, the Ugi reaction may include, for example, reacting OCF-I or OCF-J with a primary or secondary amine (such as the amines disclosed above), a methyl isocyanate, and an aldehyde to generate the corresponding Ugi condensation product.

[0061] The reactants and products of OCF-I and OCF-J follow the following reaction scheme:

[0062] The reactants and products of OCF-M and OCF-N follow the following protocol:

[0063]

[0064] In some embodiments, the Passerini reaction may include, for example, the reaction of OCF-I or OCF-J with a methyl isocyanate and an aldehyde or ketone to generate the corresponding Passerini condensation product.

[0065] The reactants and products of OCF-I and OCF-J follow the following protocol:

[0066]

[0067] The reactants and products of OCF-M and OCF-N follow the following protocol:

[0068]

[0069] In some embodiments, fentanyl analogues are prepared by a condensation reaction of carbodiimide with an amine, and these analogues may be represented by formula (I), formula (II), formula (III), or formula (IV):

[0070] Formula (I):

[0071]

[0072] Where R 1 For H, R 2 For H or CH3, R 3For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3. In a preferred embodiment, R 1 For H or OH, R 2 For H, R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3; or R1 is H or OH, R2 is CH3, and R3 is CH3.

[0073] Equation (II):

[0074]

[0075] Where R 1 For H or OH, R 2 For H or CH3, R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3. In a preferred embodiment, R 1 For H or OH, R 2 For H, R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3; or R 1 For H or OH, R 2 CH3, R 3 It is CH3.

[0076] Equation (III):

[0077]

[0078] Where R 1 H or OH, Z is an ester, thioester, acid anhydride, acyl chloride, amide or carboxylate ion.

[0079] Formula (IV):

[0080]

[0081] Where R 1 H or OH, Z is an ester, thioester, acid anhydride, acyl chloride, amide or carboxylate ion.

[0082] In some embodiments, ASP7 is converted to ASN7 via a carbodiimide (e.g., EDC)-mediated condensation reaction of OCF-I and OCF-J with ammonia, thereby yielding OCF-A and OCF-B variants (named OCF-S1 and OCF-S2). Figure 5A (Table 5). Observation of electrospray ionization mass spectrometry (ESI-MS) data of the ammonia reaction recovered the OCF-A and OCF-B variants, but also generated another product with masses of 1183.56 Da and 1998.57 Da (OCF-S15 and OCF-S16). The masses of these variants in the reaction correspond to unwanted dehydration byproducts of OCF-I and OCF-J, named OCF-S15 and OCF-S16. This byproduct was not observed by mass spectrometry in OCP-M and OCF-N (GLU7 variant) due to its low abundance.

[0083] In some embodiments, other amines may be used in the condensation reaction, preferably amines linked to a prodrug functional group. In preferred embodiments, the prodrug functional group is a methyl succinate, benzyl succinate, ether, phosphate group, or any other recognized prodrug functional group, including Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D. The prodrug functional groups disclosed in T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008 Mar; 7(3):255-70. doi:10.1038 / nrd2468. Erratumin: Nat Rev Drug Discov. 2008 Mar; 7(3):272 are incorporated herein by reference in their entirety.

[0084] In some embodiments, it may not be possible to directly achieve condensation using certain amines (e.g., ethanolamine, 3-amino-1-butanol, 4-amino-1-butanol, 3-amino-1-propanol, 3-aminopropyl-dihydrophosphate, or amino alcohols with longer alkyl chains (e.g., n-amino-n-alkyl-1-ol)). Therefore, a portion of the amine, such as the hydroxyl group, may be protected prior to condensation. In some embodiments, 3-amino-1-propanol is protected with tert-butyldimethylsilyl (TBS) by adding, for example, 1 molar equivalent of 3-amino-1-propanol, triethylamine, and tert-butyldimethylchlorosilane (TBS-Cl) to dichloromethane (DCM). In some embodiments, the reaction mixture is mixed and incubated at room temperature for at least about 4, 5, 6, 7, 8, 9, 10, or longer. The resulting oil layer after incubation contains the protected 3-amino-1-propanol and is used as the amine in the condensation reaction. In some embodiments, 1 molar equivalent of 3-aminopropyl-dihydrogen phosphate, triethylamine, and TBS-Cl are incubated in a DCM. The reaction mixture is mixed, and an equal volume of 35% acetonitrile (65% double-distilled water) and 0.1% trifluoroacetic acid is added, followed by incubation at room temperature for at least about 4, 5, 6, 7, 8, 9, 10, or longer. The upper aqueous phase contains protected 3-aminopropyl-dihydrogen phosphate, which is subsequently used for the condensation reaction.

[0085] In some embodiments, the prodrug functional group (e.g., methyl succinate or benzyl succinate) may be coupled to an amine prior to the condensation reaction. In a preferred embodiment, tert-butyloxycarbonyl (Boc)-3-amino-1-propanol (Boc-3-amino-1-propanol), allyloxycarbonyl (Alloc)-3-amino-1-propanol (Alloc-3-amino-1-propanol), or benzyloxycarbonyl (Cbz)-3-amino-1-propanol (Cbz-3-amino-1-propanol) is first coupled to a methyl or benzyl succinate. In some embodiments, alternatives to the Boc hydroxyl protecting group include, for example, methoxymethyl ether, tetrahydropyranyl ether, allyl ether, benzyl ether, tert-butyldimethylsilyl ether, tert-butyldiphenylsilyl ether, acetate, neopentanoate, or benzoate. In a preferred embodiment, 1 molar equivalent of 3-amino-1-propanol, N,N′-dicyclohexylcarbodiimide (DCC), methylsuccinate / benzylsuccinate, and 0.1 molar equivalent of 4-dimethylaminopyridine (DMAP) are added to anhydrous dimethylformamide (DMF). In some embodiments, the reaction is stirred at room temperature for at least about 12, 13, 14, 15, 16, 17, 18, 19, 20, or longer. In some embodiments, the prodrug functional group coupled to the amine may be further purified from the reaction mixture.

[0086] In some embodiments, cyproterone analogs (according to formulas (V) and (VI)) are prepared using an amine (e.g., 3-amino-1-propanol), such as OCF-S19 and OCF-S20 (Table 5) containing a terminal hydroxyl group. In some embodiments, the terminal hydroxyl group of the cyproterone analog links the cyproterone to a prodrug functional group (e.g., a phosphate group, methyl succinate, ether, or benzoate). Formula (V):

[0087]

[0088] Where R1 is H or OH, and R2 is a prodrug functional group;

[0089] Formula (VI):

[0090]

[0091] R1 is H or OH, and R2 is a prodrug functional group.

[0092] In some embodiments, the prodrug functional group, as a prodrug moiety, can be removed by chemical or enzymatic action. In some embodiments, the prodrug is activated in the subject by an enzyme or chemical substance, such as an enzyme or chemical substance found in the blood or cells. In some embodiments, the enzyme is a phosphatase, esterase, or protease. In some embodiments, the chemical or enzymatic removal of the prodrug functional group, as a prodrug moiety, yields OCF-S19 and OCF-S20. Other prodrug moieties may use a linker to leave a group at the ASP7 position via a phosphatase, esterase, or protease.

[0093] In some embodiments, cyproterin analogs (according to formulas (I) and (II)) are prepared using amines (e.g., but-3-yn-1-amine), such as OCF-S23 and OCF-S24 (Table 5) containing a terminal alkynyl group. In some embodiments, the terminal alkynyl group of the cyproterin analog can be used in subsequent "click chemistry" reactions to link cyproterin to a functional group (e.g., an azide group).

[0094] In some embodiments, analogues of cytosine are shown in formulas (VII) and (VIII):

[0095] Equation (VII):

[0096]

[0097] Where R 1 It is H or OH;

[0098] Formula (VIII):

[0099]

[0100] Where R 1 It can be H or OH.

[0101] In some embodiments, other amines may be used in the condensation reaction, preferably amines that are antibodies or antibody-linked amines. In a preferred embodiment, the antibody is a monoclonal antibody. In some embodiments, the aforementioned condensation reaction is used to modify ASP7 residues to contain a linker conjugated to a monoclonal antibody, thereby achieving a targeted delivery system for specific cancer cells.

[0102] In some embodiments, the antibody may target at least one antigen, including, for example, CD19, CD3E, ERBB2 (HER2), EGFR, MS4A1 (CD20), CD22, PDCD1 (PD-1), MSLN (mesothelin), ERBB3 (Her3), Th17 cytokine, IL17A, or any other antigen currently targeted by an antibody for the treatment of cancer or any other disease as disclosed in Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018 Jan; 9(1):86-120. doi:10.1007 / s13238-017-0457-8. Epub 2017 Aug 18, which is incorporated herein by reference in its entirety. In some embodiments, the antibody is muromonab-CD3, abciximab, rituximab, daclizumab, infliximab, palivizumab, trastuzumab, etanercept, basiliximab, gemtuzumab, or oxazolidin. ozogamicin, alemtuzumab, ibritumomabtiuxetan, adalimumab, alefacept, omalizumab, tositumomab-I131, efalizumab, cetuximab, bevacizumab, natrol Natalizumab, abatacept, ranibizumab, panitumumab, eculizumab, rilonacept, romiplostim, golimumab, ustikinumab, catumaxomab, certolizumab (polyethylene glycol)pegol, canakinumab, ofatumumab, tocilizumab, denosumab, belimumab, ipilimumab, belacitabine, brentuximab vedotin, aflibercept, mogamulizumab, pertuzumab, ziv-aflibercept, raxibacumab, trastuzumab-bemtansine conjugate, obituzumab, eltrombopag alfa, ramucirumab, siltuximab, vedolizumab, efmoroctocog alfa, pembrolizumab, dulaglutide, alemtuzumab, blinatumomab, nivolumab, secukinumab, dinutuximab, alirocumab, evolocumab, idarucizumab, asfotase Alfa, mepolizumab, daratumumab, necitumumab, elotuzumab, obiltoxaximab, ixekizumab, reslizumab, atezolizumab, daclizumab, olaratumab, bezlotoxumab, brodalumab, avelumab, dupilumab, ocrelizumab, durvalumab, any other antibody disclosed in “Strohl WR, 2017”, or any combination thereof.

[0103] This disclosure pertains to salts of fluorescein analogues.

[0104] In some embodiments, this disclosure provides salts of the fentanyl analogues described herein. These salts may be salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanate, sulfuric acid, and phosphoric acid; salts formed with organic acids, such as trifluoroacetic acid (TFA), formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid; or salts formed with bases, such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, tri-alkyl, and arylamines, as well as substituted ethanolamines.

[0105] Further salts include: (1) acid addition salts formed from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or from organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid. Salts formed by the formation of acids, camphor sulfonic acid, 4-methylbicyclo[2.2.2]oct-2-en-1-carboxylic acid, glucohepanoic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthenic acid, salicylic acid, stearic acid, mucoconic acid, etc.; or (2) when the acidic protons present in the parent cytosine analogue are replaced by metal ions (e.g., alkali metal ions, alkaline earth metal ions or aluminum ions), or when coordinated with organic bases (e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucosamine, etc.). Salts also include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; when the cytosine analogue contains a basic functional group, salts formed with non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, methanesulfonate, acetate, maleate, oxalate, etc.

[0106] Some embodiments provide amorphous forms of the cytosine analog salts disclosed herein. Such amorphous forms are advantageous for oral, pulmonary, buccal, vaginal, or suppository delivery.

[0107] Route of administration and dosage form

[0108] In some embodiments, cyproterone analogues can be administered intramuscularly, subcutaneously, intrathecally, intravenously, or intraperitoneally by infusion or injection. Solutions of cyproterone analogues can be prepared with water or selectively mixed with non-toxic surfactants. Under normal storage and use conditions, these formulations may contain preservatives to prevent microbial growth.

[0109] Pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions, or sterile powders containing cyproterone analogues, suitable for the ad hoc preparation of sterile injectable or infusion solutions or dispersions, and may also be selectively encapsulated in liposomes. Preferably, the final dosage form should be sterile, fluid, and stable under production and storage conditions. The liquid carrier or medium may be a solvent or liquid dispersion medium, such as water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, non-toxic glycerides, cyclodextrins, and suitable mixtures thereof. Appropriate fluidity can be maintained, for example, by forming liposomes, maintaining the desired particle size of the dispersion, or by using surfactants. Microbial action can be prevented by a variety of antimicrobial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.). In many cases, isotonic agents, such as sugars, buffers, or sodium chloride, are preferred. Long-term absorption of injectable compositions can be achieved by using agents that delay absorption (e.g., aluminum monostearate and gelatin) in the composition.

[0110] The method for preparing a sterile injectable solution involves adding a cytosine analogue to a suitable solvent in the required amount, and adding other components as needed, preferably followed by filtration for sterilization. For sterile powders used in the preparation of sterile injectable solutions, preferred methods include vacuum drying and freeze-drying techniques, which yield active ingredient powders as well as any other desired components present in the previously sterile filtered solution.

[0111] The compositions disclosed herein can also be administered orally with pharmaceutically acceptable carriers, such as inert diluents or assimilated edible carriers. They can be encapsulated in hard or soft gelatin capsules, compressed into tablets, or directly incorporated into the subject's diet.

[0112] For oral therapeutic administration, cyproterone analogues may be combined with one or more excipients and used in the form of ingestible tablets, buccal lozenges, lozenges, capsules, elixirs, suspensions, syrups, thin tablets, etc. Such compositions and formulations should contain at least 0.1% of the cyproterone analogue disclosed herein. Of course, the percentage of the cyproterone analogue disclosed herein in these compositions and formulations can vary, and is generally conveniently between about 2% to about 60% by weight of a given unit dose form. The amount of cyproterone analogue in such therapeutically useful compositions should be sufficient to achieve an effective dose level.

[0113] Tablets, lozenges, pills, capsules, etc. may also contain one or more of the following ingredients: binders (such as tragacanth gum, gum arabic, corn starch or gelatin); excipients (such as dicalcium phosphate); disintegrants (such as corn starch, potato starch, alginic acid, etc.); lubricants (such as magnesium stearate); and sweeteners (such as sucrose, fructose, lactose or aspartame), or flavorings (such as peppermint, wintergreen oil or cherry flavoring).

[0114] When the unit dosage is in capsule form, in addition to the materials of the above types, it may also contain a liquid carrier, such as vegetable oil or polyethylene glycol.

[0115] Various other materials can be used as coatings or to otherwise alter the physical form of solid unit dosage forms. For example, tablets, pills, or capsules can be coated with gelatin, wax, shellac, or sugar. Syrups or elixirs may contain cyproconazole analogs, sucrose or fructose as sweeteners, methylparaben and propylparaben as preservatives, dyes, and flavorings such as cherry or orange.

[0116] Of course, any material used to prepare any unit dose form should be pharmaceutically acceptable and substantially non-toxic at the dose used.

[0117] Furthermore, cyproterone analogues can be incorporated into sustained-release formulations and devices. For example, cyproterone analogues can be incorporated into time-release capsules, time-release tablets, time-release pills, or time-release cyproterone analogues or nanoparticles.

[0118] Pharmaceutical compositions for the topical application of fentanyl analogues to the epidermis (mucosa or skin surface) can be formulated as ointments, creams, lotions, gels, or as transdermal patches. Such transdermal patches may contain penetration enhancers such as linalool, cyclodextrin, carvacrol, thymol, citral, menthol, p-anetinoside, etc. Ointments and creams may, for example, comprise an aqueous or oil-based base and contain suitable thickeners, gelling agents, colorants, etc. Lotions and creams may comprise an aqueous or oil-based base and typically also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners, colorants, etc. Gels preferably comprise an aqueous carrier base and contain gelling agents such as cross-linked polyacrylic acid polymers, modified polysaccharides (e.g., carboxymethyl cellulose), etc.

[0119] Pharmaceutical compositions suitable for topical oral administration (e.g., buccal or sublingual administration) include lozenges consisting of a composition and a flavoring matrix (such as sucrose, gum arabic, or astragalus gum); tablets consisting of a composition and an inert matrix (such as gelatin and glycerin, or sucrose and gum arabic); and mouthwashes consisting of an active ingredient and a suitable liquid carrier. Pharmaceutical compositions for topical oral administration may, as needed, include a penetration enhancer.

[0120] Useful solid carriers include fine powders such as talc, clay, microcrystalline cellulose, silica, and alumina. Other solid carriers include non-toxic polymer nanoparticles or microparticles. Useful liquid carriers include water, alcohols, or glycerol, or water / alcohol / glycerol mixtures, in which fluoride analogs can be dissolved or dispersed to effective levels, and selectively with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antibacterial agents can be added to optimize performance for specific applications. The resulting liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using a pump or aerosol sprayer.

[0121] Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified cellulose, or modified mineral materials can also be used with liquid carriers to form spreadable pastes, gels, ointments, soaps, etc., which can be applied directly to the user's skin.

[0122] Useful dermatological compositions for delivering cytosine analogues to the skin are known in the art; see, for example, Jacquet et al. (U.S. Patent No. 4,608,392), Geria (U.S. Patent No. 4,992,478), Smith et al. (U.S. Patent No. 4,559,157), and Wortzman (U.S. Patent No. 4,820,508), all of which are incorporated herein by reference in their entirety.

[0123] The concentration of virucidal analogues in these formulations can vary widely depending on the nature of the formulation and the intended route of administration. For example, the concentration of virucidal analogues in liquid compositions (such as lotions) is preferably about 0.1-25% by weight, more preferably about 0.5-10%. The concentration in semi-solid or solid compositions (such as gels or powders) is preferably about 0.1-5% by weight, more preferably about 0.5-2.5%.

[0124] Pharmaceutical compositions for spinal administration or amniocentesis may be provided in unit dose form in ampoules, pre-filled syringes, small-volume infusions, or multi-dose containers and may contain added preservatives. Compositions for parenteral administration may be suspensions, solutions, or emulsions and may contain adjuvants such as suspending agents, stabilizers, and dispersants.

[0125] Pharmaceutical compositions suitable for rectal administration comprise a combination of the cytosine analogues of this disclosure with a solid or semi-solid (e.g., cream or paste) carrier or matrix. For example, such rectal compositions may be provided as unit-dose suppositories. Suitable carriers or matrices include cocoa butter and other materials commonly used in the art.

[0126] According to one embodiment, this disclosure provides pharmaceutical compositions suitable for vaginal administration, which are provided in the form of suppositories, tampons, creams, gels, pastes, foams, or sprays, containing a cytosine analog of this disclosure and combined with a carrier known in the art (e.g., cyclodextrin). Alternatively, the compositions suitable for vaginal administration may be delivered in liquid or solid dosage forms.

[0127] This disclosure also covers pharmaceutical compositions suitable for intranasal administration. Such intranasal compositions comprise the cytosine analogue of this disclosure, a carrier, and a suitable delivery device for delivering a liquid spray, dispersible powder, or drops. Drops may be formulated with an aqueous or non-aqueous matrix and may also contain one or more dispersants, solubilizers, or suspending agents. Liquid sprays may be conveniently delivered by a pressurized container, blower, nebulizer, or other convenient means of delivering an aerosol containing a cytosine analogue. The pressurized container contains a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gases known in the art. The aerosol dosage can be controlled by providing a valve to deliver a measured amount of the cytosine analogue.

[0128] The cytomegalocin analogue can be mixed with an inert powder carrier and inhaled or blown into the subject's lungs.

[0129] Pharmaceutical compositions for inhalation or inhalation administration may be in the form of dry powder compositions, such as a powder mixture of a cytosine analogue and a suitable powder matrix (such as lactose or starch). Such powder compositions may be in unit dose form, such as capsules, cartridges, gelatin packets, or blister packs, from which the powder can be administered by means of an inhaler or inhaler.

[0130] The exact dosage (effective dose) of cytomegalocin analogues varies from subject to subject, depending on factors such as species, age, weight, and the subject's general or clinical condition, the severity or mechanism of the infection being treated, the specific reagent or carrier used, the method of administration, and the timing of administration. The therapeutically effective dose can be determined empirically using conventional methods known to those skilled in the art. See, for example, *The Pharmacological Basis of Therapeutics*, edited by Goodman and Gilman, Macmillan Publishing Co., New York. For example, the effective dose can initially be estimated using in vivo assays or suitable animal models. Animal models can also be used to determine appropriate concentration ranges and routes of administration. This information can then be used to determine the useful dose and route of administration in humans. Methods for extrapolating effective doses in mice and other animals to humans are known in the art; see, for example, U.S. Patent No. 4,938,949, which is incorporated herein by reference in its entirety. The therapeutic dose can also be selected by analogy with the doses of similar therapeutic agents.

[0131] The specific dosing regimen and dosage can be selected by the attending clinician based on the specific circumstances (e.g., the subject, the disease, the disease state involved, and whether the treatment is prophylactic). Treatment may involve daily or multiple daily doses for several days to months, or even years.

[0132] However, a suitable dosage range is typically from about 0.001 to about 100 mg / kg body weight per day, preferably from about 0.01 to about 100 mg / kg body weight per day, more preferably from about 0.1 to about 50 mg / kg body weight per day, and even more preferably from about 1 to about 10 mg / kg body weight per day. For example, a suitable dosage might be about 1 mg / kg, 10 mg / kg, or 50 mg / kg body weight per day.

[0133] The cytomegalocin analogues can be conveniently administered in unit doses, each containing, for example, about 0.05 to about 10,000 mg, about 0.5 to about 10,000 mg, about 5 to about 1,000 mg, or about 50 to about 500 mg of the active ingredient.

[0134] Cyclosporine analogues can be administered to achieve, for example, peak plasma concentrations of about 0.25 to about 200 μM, about 0.5 to about 75 μM, about 1 to about 50 μM, about 2 to about 30 μM, or about 5 to about 25 μM. Exemplary ideal plasma concentrations include at least 0.25, 0.5, 1, 5, 10, 25, 50, 75, 100, or 200 μM. For example, plasma levels may be about 1 to about 100 micromoles or about 10 to about 25 micromoles. This can be achieved, for example, by intravenous injection of a solution containing 0.05 to 5% cyclosporine analogue (optionally in saline) or by oral administration of a bolus dose containing about 1 to about 100 mg cyclosporine analogue. Ideal plasma levels can be maintained by continuous or intermittent infusion.

[0135] The cytomegalocin analogue may be included in the composition at a concentration range that is therapeutically useful and effective, the range of which is determined by conventional methods well known in the medical and pharmaceutical fields. For example, a typical composition may contain one or more cytomegalocin analogues at a concentration range of at least about 1 mg / ml, preferably at least about 4 mg / ml, more preferably at least 5 mg / ml, and most preferably at least 6 mg / ml.

[0136] Cyclosporin analogues can be conveniently administered as a single dose or in multiple doses at appropriate time intervals, such as once daily or twice, three, four or more times daily. The doses themselves can be further subdivided, for example, into several discrete, loosely spaced doses, such as multiple inhalations from an inhaler.

[0137] Optionally, the pharmaceutical compositions of this disclosure may comprise one or more other therapeutic agents, for example, as a combination therapy. The additional therapeutic agents will be contained within a concentration range that is therapeutically useful and effective in the composition, a concentration range determined by conventional methods well known in the medical and pharmaceutical fields. The concentration of any particular additional therapeutic agent may be the same as the typical concentration range when the agent is used as monotherapy, or, if there is a synergistic effect when used in combination with a cytosine analogue of this disclosure, the concentration may be lower than the typical monotherapy concentration.

[0138] Treatment

[0139] In some embodiments, the cytomegalocin analogs disclosed herein exhibit antifungal activity, particularly against Candida spp. and Saccharomyces spp. Therefore, certain embodiments of this disclosure provide methods for administering cytomegalocin analogs to a subject in need to treat or prevent infection, particularly fungal infections, more particularly yeast infections, and even more particularly Candida infections. In certain embodiments, this disclosure provides methods for treating or preventing infections caused by fungi selected from the genus *Candida*, *Saccharomyces*, *Trichophyton*, *Rhizopus*, *Mucor*, *Fusarium*, *Aspergillus*, or *Cryptococcus*, including, for example, *Trichophyton mentagrophytes*, *Trichophyton rubrum*, *Rhizopus microsporus*, *Mucorcircinelloides*, *Mucor fragilis*, *Fusarium solani*, *Fusarium oxysporum*, and *Aspergillus flavus*. Candida flavus, Aspergillus fumigatus, Candida albicans, Candida glabrata, Candida krusei, Candida auris, Candida parapsilosis, Candida tropicalis, Saccharomyces cerevisiae, or Cryptococcus neoformans.

[0140] In some embodiments, the cytomegalovirus analogs disclosed herein exhibit antiparasitic activity, particularly against Cryptosporidium spp., including, for example, Cryptosporidium parvum, Entamoeba histolytica, Giardia duodenalis, or Trichomonas vaginalis. Therefore, certain embodiments of this disclosure provide a method for administering cytomegalovirus analogs to a subject in need to treat or prevent parasitic infections.

[0141] In some embodiments, cytomegalocin analogs can be used for cancer treatment. In some embodiments, cytomegalocin analogs exhibit anticancer activity, including, for example, anticancer activity against ovarian cancer, astrocytoma brain cancer (SW1088), and B-cell non-Hodgkin lymphoma. The resulting cytomegalocin analogs can be engineered to conjugate with antibodies targeting specific tumors or cancer cell lines. In some embodiments, the antibodies can be engineered to deliver an enzyme that activates the prodrug form of the cytomegalocin analog at the tumor or infectious agent site.

[0142] Cancers suitable for treatment according to the disclosed methods include, but are not limited to: acanthoma, acinic cell carcinoma, acoustic neuroma, acrallentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloid dendritic cell leukemia, acute myeloid leukemia, and acute promyelocytic leukemia. The following are cancer types: promyelocyticleukemia, adamantinoma, adenocarcinoma, adenoid cysticcarcinoma, adenoma, adenomatoid odontogenic tumor, adrenocortical carcinoma, adult T-cell leukemia, aggressive NK-cell leukemia, AIDS-related cancers, AIDS-related lymphoma, alveolar soft part sarcoma, ameloblastic fibroma, anal cancer, anaplastic large cell lymphoma, anaplastic thyroid cancer, and angioimmunoblastic T-cell lymphoma.T-cell lymphoma, angiomyolipoma, angiosarcoma, appendix cancer, astrocytoma, atypical teratoid rhabdoid tumor, basal cell carcinoma, basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, bile tract cancer, bladder cancer, blastoma, bone cancer, bone tumor, breast cancer, Brenner tumor, bronchial tumor, bronchioloalveolar carcinoma, brown tumor Tumor, Burkitt's lymphoma, Cancer of unknown primary site, Carcinoid tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of unknown primary site, Carcinosarcoma, Castleman disease, Central nervous system embryonal tumor, Cerebellar astrocytoma, Cerebral astrocytoma, Cervical cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papillomaPlexus papilloma, Chronic lymphocytic leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic myeloproliferative disorder, Chronic neutrophilic leukemia, Clear-cell tumor, Colon cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B-cell lymphoma Lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermalsinus tumor, Endometrial cancer, Endometrial uterine cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymoblastoma, Ependymoma, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing family of tumors, Ewing sarcoma, Extracranial germ cell tumorTumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, extramammary Paget's disease, fallopian tube cancer, fetus in fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, gallbladder cancer, ganglioglioma, ganglioneuroma, gastric cancer, gastric lymphoma, gastrointestinal cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, germ cell tumor, gestational choriocarcinoma. Choriocarcinoma, Gestational trophoblastic tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy cell leukemia, Head and neck cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy, Hepatocellular carcinomaHepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin's lymphoma, Hypopharyngeal cancer, Hypothalamic glioma, Inflammatory breast cancer, Intraocular melanoma, Islet cell carcinoma, Islet cell tumor, Juvenile myelomonocytic leukemia, Kaposi's sarcoma, Kidney cancer, Klatskin tumor, Krukenberg tumor, Laryngeal cancer, Lentigo maligna melanoma Melanoma, Leukemia, Lip and oral cavity cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant fibrous histiocytoma, Malignant fibrous histiocytoma of bone, Malignant glioma, Malignant mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant tritonTumors, Mucosa-associated lymphoid tissue lymphoma (MALT lymphoma), Mantle cell lymphoma, Mast cell leukemia, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloepithelioma, Melanoma, Meningioma, Merkel cell carcinoma, Mesothelioma, Metastatic squamous neck cancer with occult primary, Metastatic urothelial carcinoma, Mixed Müllerian tumor, Monocytic leukemia, Mouth cancer Cancer, mucinous tumor, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplasia disease, myelodysplasia syndromes, myeloid leukemia, myeloid sarcoma, myeloproliferative disease, myxoma, nasal cavity cancer, nasopharyngeal cancer, nasopharyngeal carcinoma, neoplasm, neuronoma, neuroblastoma, neurofibroma, neuroma, nodular melanomaMelanoma, Non-Hodgkin's lymphoma, Nonmelanoma skin cancer, Non-small cell lung cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral cancer, Oropharyngeal cancer, Osteosarcoma, Ovarian cancer, Ovarian epithelial cancer, Ovarian germ cell tumor, Ovarian low malignant potential tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic cancer. Cancer, papillary thyroid cancer, papillomatosis, paraganglioma, paranasal sinus cancer, parathyroid cancer, penile cancer, perivascular epithelioid cell tumor, pharyngeal cancer, pheochromocytoma, intermediately differentiated pineal parenchymal tumor, pineoblastoma, pituitary adenoma, pituitary tumor, plasma cell neoplasm, pleuropulmonary blastomablastoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary hepatocellular carcinoma, primary liver cancer, primary peritoneal cancer, primitive neuroectodermal tumor, prostate cancer, pseudomyxoma peritonei, rectal cancer, renal cell carcinoma, and respiratory tract carcinoma involving the NUT gene on chromosome 15. 15) Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary gland cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma, Secondary neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sézary syndrome, Signet ring cell carcinoma, Skin cancer, Small blue round cell tumor, Small cell carcinomaSmall cell lung cancer, small cell lymphoma, small intestine cancer, soft tissue sarcoma, somatostatinoma, soot wart, spinal cord tumor, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, stomach cancer, superficial spreading melanoma, supratentorial primitive neuroectodermal tumor, surface epithelial-stromal tumor, synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia. Leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, teratoma, terminal lymphatic cancer, testicular cancer, theca cell tumor, throat cancer, thymic carcinoma, thymoma, thyroid cancer, transitional cell cancer of renal pelvis and ureter, transitional cell carcinoma, urachal cancer, urethral cancer, urogenital neoplasm, uterine sarcoma.Sarcoma, uveal melanoma, vaginal cancer, Verner-Morrison syndrome, Verrucous carcinoma, visual pathway glioma, vulvar cancer, Waldenstrom macroglobulinemia, Warthin's tumor, Wilms' tumor, or any combination thereof.

[0143] In some embodiments, the cancers treated according to this disclosure are skin cancer, particularly melanoma; rectal cancer; bladder cancer; cervical cancer; head and neck cancer; thyroid cancer; breast cancer; prostate cancer; uterine cancer; colon cancer; adrenal cancer; hepatocellular carcinoma; lung cancer, particularly lung adenocarcinoma or lung squamous cell carcinoma; or kidney cancer, particularly renal chromoma, clear cell renal carcinoma or papillary renal carcinoma; or glioma / glioblastoma.

[0144] Methods of treating or preventing infection or cancer can be performed in any subject (e.g., mammals, including humans). Such methods include administering an effective amount of the cytosine analogue of this disclosure to a subject who requires prevention or treatment of an infection or cancer. Cytosine analogues can be administered in the form of pharmaceutical compositions of cytosine analogues.

[0145] Preferably, cyproterone analogues are administered via parenteral or enteral routes. More preferably, cyproterone analogues are administered via intravaginal, intraperitoneal, subcutaneous, or intravenous routes. The effective dose of cyproterone analogues may vary depending on the age and condition of the subject being treated. However, suitable unit doses are generally between about 0.01 and about 100 mg. For example, unit doses may range from about 0.2 mg to about 50 mg. Such unit doses may be administered more than once daily, for example, twice or three times daily.

[0146] In some embodiments, this disclosure also provides a culture medium. For example, the culture medium may contain or consist of ddH₂O, supplemented with dipotassium hydrogen phosphate, ammonium chloride, magnesium sulfate heptahydrate, and a carbon source. In a preferred embodiment, the carbon source is an amino acid or a derivative thereof, citrate, cis-aconitate, D-isocitrate, α-ketoglutarate, succinyl-CoA, succinic acid, fumarate, malic acid, oxaloacetic acid, pyruvate, or acetyl-CoA. In some embodiments, the concentration of dipotassium hydrogen phosphate is about 1 g / L to about 100 g / L, or about 5 g / L to about 50 g / L, or about 9 g / L; the concentration of ammonium chloride is about 0.1 g / L to about 10 g / L, or about 0.5 g / L to about 5 g / L, or about 1 g / L; the concentration of magnesium sulfate heptahydrate is about 0.01 g / L to about 10 g / L, or about 0.1 g / L to about 1 g / L, or about 0.2 g / L; and the concentration of the carbon source is about 0.1 g / L to about 10 g / L, or about 0.5 g / L to about 5 g / L, or about 1 g / L.

[0147] This disclosure also provides a method for culturing Burkholderia contaminated with the cytomegalovirus for producing the cytomegalovirus analogues, such as culturing B. contaminants MS14. In these methods, the cells may be cultured in the culture medium at a temperature of about 20°C to about 30°C (e.g., about 28°C) for 6 hours to about 10 days or longer (e.g., about 6 to 24 hours, or about 4 days to about 10 days, or about 4, 5, 6, 7, 8, 9 or 10 days).

[0148] Materials and Methods

[0149] Product separation

[0150] Primary cultures were prepared in 2L culture flasks, consisting of 1L double-distilled water (ddH2O) supplemented with dipotassium hydrogen phosphate (9 g / L), ammonium chloride (1 g / L), magnesium sulfate heptahydrate (0.2 g / L), and L-asparagine (1 g / L). The pH of the culture was adjusted to 7.0–7.2 before autoclaving for 20 minutes. Secondary cultures were prepared in 2.8L culture flasks, consisting of 900ml double-distilled water (ddH2O) supplemented with dipotassium hydrogen phosphate (9 g / L), ammonium chloride (1 g / L), magnesium sulfate heptahydrate (0.2 g / L), and L-asparagine (1 g / L). The pH of the culture was adjusted to 7.0–7.2 before autoclaving for 20 minutes. 1ml of frozen glycerol inoculum of *B. contaminans* MS14 was added to the overnight culture, and the culture was incubated on a shaker at 28°C and 150 RPM. Check the OD600 of the primary culture within 8 to 15 hours, and when the OD600 reaches 0.65-0.9, add 100 ml of the primary culture to each secondary culture flask. Incubate the secondary cultures at 28°C for 3-7 days without shaking, then proceed with extraction. Before extraction, combine the secondary cultures and heat to 55°C-60°C to inactivate bacteria, then cool to 40°C or below.

[0151] The column was prepared by packing it with Amberlite XAD1140 resin, using at least 2 grams of resin per liter of culture to be extracted. Before packing the column, the resin was immersed in 80% isopropanol and mixed at room temperature for 30 minutes, then the supernatant was discarded. The resin was then immersed in double-distilled water and mixed at room temperature for 15 minutes, then the supernatant was discarded; this washing step was repeated twice. After washing, the resin was packed into the column. The resin could be used for up to four extractions, after which it was discarded. A peristaltic pump was attached to the column using a Masterflex tube, and the pump flow rate was measured. The inactivated culture was pumped through the column, circulating four times the total volume. The resin was then rinsed with at least 75 ml of double-distilled water per gram of resin. The resin was then rinsed with at least 150 ml of a solution of 20% isopropanol (IPA) in double-distilled water containing 0.1% trifluoroacetic acid (TFA) for at least 30 minutes. The resin was then washed twice with at least 150 ml of a solution of 80% IPA in double-distilled water containing 0.1% TFA, each time for at least 60 minutes, to elute the active compound. The eluates of 80% IPA were combined and dried on an evaporator or rotary evaporator to remove IPA. The aqueous phase was centrifuged at 13,000 g, and the resulting precipitate was resuspended in 35% acetonitrile (ACN) containing 0.1% TFA. The resulting substance was further purified by reversed-phase high-performance liquid chromatography (RP-HPLC).

[0152] Product purification

[0153] The product was purified by reversed-phase high-performance liquid chromatography (RP-HPLC) using a SinoChrom ODS-BP 5 μm (10.0 mm x 250 mm, SN: 3018159x) column. The mobile phase was acetonitrile (ACN) containing 0.1% trifluoroacetic acid (TFA) and double-distilled water (ddH2O). The gradient was changed from 90% ddH2O to 20% ddH2O over 30 minutes. The cytosine eluted at approximately 45%–43% ddH2O (containing 0.1% TFA). The sample could then be further purified to separate different variants of cytosine. The collected peaks were analyzed on a Supercell ODS2 5 μm (4.6 mm x 250 mm, SN: E3018660) column with acetonitrile (ACN) containing 0.1% formic acid (FA) and 10 mM triethylamine as the mobile phase. The gradient was changed from 90% 10mM triethylamine to 60% 10mM triethylamine and held for 10 minutes, then decreased to 20% 10mM triethylamine. Different variants of cytosine were eluted during the isocratic elution phase at 60% 10mM triethylamine.

[0154] Mass spectrometry (MS)

[0155] Mass spectrometry (MS) analysis was performed using a ThermoFisher Q Exactive Orbitrap mass spectrometer (ESI-MS) or a Bruker Ultraflextreme MALDI-TOF-TOF mass spectrometer to confirm the product.

[0156] For ESI-MS, the compound was dissolved in 50% acetonitrile (ACN) containing 0.1% formic acid (FA) at a concentration of 1 μg / mL or higher. The sample was injected directly at a flow rate of 1 μL / min. A protonated molecular ion peak of the compound was observed.

[0157] For MALDI-TOF MS, the sample was mixed with α-cyano-4-hydroxycinnamic acid matrix (10 mg / ml) at a 1:1 ratio, spotted onto a MALDI-TOF plate, and allowed to dry. Sample analysis was performed in reflectance mode using low laser power settings (instrument: ultrafXtreme TOF / TOF (Bruker corporation, Billerica, AM); software: flexControl (version 3.4.135.12) / flex analysis (3.4.78.0)) (laser: repetition rate -1000 Hz; laser shots -1000; beam focus -6; beam attenuation -70) (mass spectrometer: polarity - positive voltage polarity; PIE delay -120 ns; reflector detector voltage -2.625 kV; lens voltage -7.8 kV; ion source 1 -20 kV; ion source 2 -17.85 kV). The sample scan range was 650–3000 Da. Mass spectrometry data obtained by MALDI-TOF showed high signal intensities for sodium (+22.98 Da) and potassium (+38.96 Da) adducts. The protonated sample showed a lower signal intensity compared to these two adducts. Due to the weaker signal intensity compared to the adducts, the protonated cytosine variant with ASN1 substituting for BHN1 was not always clearly observed.

[0158] Nuclear magnetic resonance (NMR)

[0159] Three to four milligrams of cyproterone sample were dissolved in 600 μl of dimethyl sulfoxide (DMSO-d6; Cambridge Isotopes), and NMR data were acquired according to previously reported methods. The 1H resonance peaks were assigned using standard methods with correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY), and nuclear Oferhausen effect spectroscopy (NOESY). Rotated coordinate system Oferhausen enhancement spectroscopy (ROESY) and 13C heteronuclear single quantum correlation (HSQC) experiments were used to clarify certain ambiguous regions in the TOCSY and NOESY spectra. The spectral widths of TOCSY, NOESY, and ROESY are typically 11.35 ppm in both dimensions. The spectral widths of HSQC are typically 11.35 ppm in the proton dimension and 100 and 150 ppm in the carbon dimension. All two-dimensional (2D) data were collected with 2,048 complex points in the acquisition dimension and 256 complex points in the indirect dimension, except for HSQC, which collected 2,048 and 128 complex points in the direct and indirect dimensions, respectively. Data were processed using nmrPipe software and analyzed using the interactive computer program NMRView.

[0160] Coverage Experiment

[0161] Yeast extract peptone glucose (YPD) agar plates (20 g / L peptone, 20 g / L glucose, 10 g / L yeast extract, 15 g / L agar) were covered with YPD soft agar medium (20 g / L peptone, 20 g / L glucose, 10 g / L yeast extract, 7.5 g / L agar) containing S. cerevisiae DGY6 (OD600 = 0.15, subsequently diluted 25 times) and allowed to solidify. The compounds in the solution were then spotted onto the plates and allowed to dry. For comparison of different compounds, equal volumes and numbers were spotted onto the plates. The plates were incubated at 35°C for 24 hours. The presence of inhibition zones was observed on the plates.

[0162] Minimum inhibitory concentration (MIC) test

[0163] Following the modified CLSIM27-A3 method, the MIC (serum MIC) experiment was performed in 96-well plates using YPD growth medium or YPD growth medium supplemented with human or mouse serum (final serum concentration 20%, final growth medium concentration 80%). The plates were incubated at 35°C for 24 hours, and the MIC value was determined by checking each well for the presence of fungi.

[0164] Preparation of semi-synthetic analogs

[0165] In the preparation of analogs containing variants at the ASP7 site, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) is used as a condensing agent to generate various amides at the carboxyl group of ASP7. Figure 5A OCF-I and OCF-J were incubated with the desired amine, EDC, and 1-hydroxybenzotriazole (HOBt) in a 10-molar excess ratio in N,N-dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) at room temperature in the dark for 16 hours or longer. Extending the incubation time or incubation at 35°C can improve the reaction efficiency of some amines (especially those with higher molecular weights). The reaction could not be completed under these conditions with incubation times of 4 hours or less. This reaction has been successfully carried out using primary amines with carbon chain lengths up to 12 carbon atoms (dodecylamine). Two primary amines with terminal alkyne groups, namely but-3-yn-1-amine and propyneamine, have also been successfully used in this reaction. The reaction can also be carried out on the GLU7 variant to generate an amide at the carboxyl group of GLU7. Figure 5B The reaction conditions are the same as those for the ASP7 variant.

[0166] The reaction cannot be achieved via direct EDC condensation using 3-amino-1-propanol. This is likely due to the presence of a hydroxyl group in the compound. The hydroxyl group of 3-amino-1-propanol is protected with tert-butyldimethylsilyl (TBS) by adding a reagent to 1 molar equivalent of 3-amino-1-propanol, triethylamine, and tert-butyldimethylchlorosilane (TBS-Cl) in dichloromethane (DCM). The reaction mixture is mixed and incubated at room temperature for at least 4 hours. The resulting oil layer contains the protected 3-amino-1-propanol and is used as an amine in the EDC condensation reaction. TBS protection of 3-aminopropyl-dihydrogen phosphate is also necessary for the preparation of the phosphate prodrugs OCF-S21 and OCF-S22. 1 molar equivalent of 3-aminopropyl-dihydrogen phosphate, triethylamine, and TBS-Cl is incubated in DCM. The reaction mixture is mixed, and an equal volume of 35% acetonitrile containing 0.1% trifluoroacetic acid is added, followed by incubation at room temperature for at least 4 hours. The upper aqueous phase contains protected 3-aminopropyl-dihydrophosphoric acid, which is used in the subsequent EDC condensation reaction.

[0167] To prepare the methyl and methylsuccinate prodrugs, Boc-3-amino-1-propanol was first coupled with either methylsuccinate or benzylsuccinate. One molar equivalent of 3-amino-1-propanol, N,N′-dicyclohexylcarbodiimide (DCC), methylsuccinate / benzylsuccinate, and 0.1 molar equivalent of 4-dimethylaminopyridine (DMAP) were added to anhydrous dimethylformamide (DMF). The reaction was stirred at room temperature for at least 12 hours. The byproduct dicyclohexylurea appeared as a white precipitate. The solution was filtered through 2-micron filter paper to remove the byproduct. Saturated ammonium chloride was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous magnesium sulfate. The ethyl acetate solution was filtered through 2-micron filter paper and dried on a rotary evaporator. The residue, the product, was dissolved in an 80% dichloromethane solution containing 20% ​​trifluoroacetic acid and allowed to stand at room temperature for 24 hours. Then, one molar equivalent of saturated sodium bicarbonate was added to neutralize the trifluoroacetic acid. The reaction solution was extracted twice with ethyl acetate, and the combined ethyl acetate extracts were dried over anhydrous magnesium sulfate and then filtered through 2-micron filter paper. The ethyl acetate solution was dried on a rotary evaporator and then dissolved in ethanol as a stock solution, stored at -20°C. The final product was confirmed by mass spectrometry. The synthesized EDC condensation reaction was quenched by diluting to 1 ml with 35% acetonitrile containing 0.1% trifluoroacetic acid and analyzed on a Supercell ODS2 5 μm (4.6 mm × 250 mm SN: E3018660) column. Peaks were collected and analyzed by MALDI-TOF or ESI-MS to confirm the expected product.

[0168] Activation of OCF-S21 / OCF-S22 phosphate prodrug

[0169] The removal of phosphate groups from OCF-S21 / OCF-S22 in vitro was achieved using calf intestinal alkaline phosphatase (QuickCIP; New England Biolabs). In the coverage assay, 5 μg of OCF-S21 / OCF-S22 (approximately 5000 pmol) was mixed with 0.25 μl of alkaline phosphatase and 0.5 μl of rCutSmart. TM The buffer (1X) and 3.25 μl of double-distilled water (ddH2O) were mixed. The reaction mixture was incubated at 37 °C for at least 90 min. The removal of the phosphate group to generate OCF-S19 / OCF-S20 was confirmed by MALDI-TOF MS and by coverage assays as described above.

[0170] The minimum inhibitory concentration (MIC) assay was performed on YPD growth medium according to the modified CLSIM27-A3 method. 10 μl of alkaline phosphatase and 2 μl of rCutSmart were added to each well. TM Prepare buffer (10X) to bring the final volume of each well to 200 μl. Contains 10 μl alkaline phosphatase and 2 μl rCutSmart. TM The negative control, which was buffered (10X) but did not contain OCF-S21 / OCF-S22, did not show any inhibitory effect on fungal growth.

[0171] All patents, patent applications, provisional applications and publications mentioned or cited herein are incorporated herein by reference in their entirety, including all figures and tables, provided that their contents do not contradict the express teachings of this specification.

[0172] The following are examples illustrating the methods of implementing this disclosure. These examples should not be construed as limiting. Unless otherwise stated, all percentages are by weight and all solvent mixing ratios are by volume.

[0173] Example 1—Aspartic acid 7-monocytocin

[0174] As detailed in the Methods section, cytosine was extracted from B. contaminans MS14 culture. Cytosine is a non-ribosomally synthesized cyclic glycopeptide composed of 8 amino acids (Figure 1). Briefly, B. contaminans MS14 culture was pumped through Amberlite XAD1180 resin, which collected cytosine and other substances. Cytosine was eluted from the resin using 80% isopropanol (IPA) containing 0.1% trifluoroacetic acid (TFA). The 80% IPA containing 0.1% TFA was dried and dissolved in 35% acetonitrile (ACN) containing 0.1% TFA. The solution was purified by reversed-phase high-performance liquid chromatography (RP-HPLC) using acetonitrile (ACN) containing 0.1% TFA and double-distilled water (ddH2O) as the mobile phase. The cytomegaloxin eluted as two peaks in the range of 45% to 43% ddH₂O (containing 0.1% TFA). These two peaks were collected and further purified using acetonitrile containing 0.1% formic acid (FA) and 10 mM triethylamine as the mobile phase. This method allows for the separation of various cytomegaloxin variants. Figure 2 Peaks 2 and 3 on the chromatogram contain OCF variants of asparagine (OCF-A and OCF-B) or glutamine (OCF-K and OCF-L), and nuclear magnetic resonance (NMR) structural analysis shows that these variants are located at residue 7. Peaks 4 and 5 contain OCF variants of aspartic acid (OCF-I and OCF-J) or glutamic acid (OCF-M and OCF-N), located at residue 7.

[0175] Table 1: Indication Figure 2 The variant eluted from the marked peak.

[0176]

[0177]

[0178] High-resolution mass spectrometry can accurately predict elemental composition, and the results show that the natural serotonin variant contains ASP, GLN, and GLU, but not ASN. Figures 3A-3B (Table 2). The presence of ASP at position 7 was confirmed by nuclear magnetic resonance (NMR) data from both samples. Figures 3A-3B Samples containing a mixture of OCF-A / OCF-B and OCF-I / OCF-J ( Figures 3A-3B The TOCSY fingerprint region shows a spin system corresponding to ASP7. The fingerprint region plays an important role in amino acid identification; in previous studies, the spin system with a proton chemical shift of 8.48 ppm has been assigned to ASN7. Figure 3AASN and ASP have similar proton chemical shifts, but ASP lacks the chemical shift corresponding to the δ proton on the terminal amide side chain of the ASN residue. This new spin system did not show a proton chemical shift corresponding to the β proton and δ proton in ASN in NOESY, therefore, this new spin system is classified as ASP. Figure 3B In the ASP spin system, nuclear Oferhauser effects (NOEs) were observed between Hα and Hβ and HN of SER8, and NOEs were also observed between Hα of Gly6 and HN of the ASP spin system. These NOE effects were also present in the ASN7 spin system with HN chemical shifts of 8.41 and 8.32 ppm, which helps confirm that the ASP residues are located at the seventh position. High-resolution mass spectrometry (HRMS) data identified OCF-L and OCF-N containing GLN7 and GLU7 residues. Figures 3A-3B (Table 2). TOCSY data revealed a new spin system with an Hα chemical shift of 8.30, assigned to GLN7. α, β, ε, and γ protons were observed in this spin system, consistent with the characteristics of GLN. NOE was observed between the Hα and Hβ of the GLN7 spin system and the HN of SER8.

[0179] Table 2. Proton chemical shifts of samples containing mixtures of OCF-A / OCF-B and OCF-I / OCF-J. The newly assigned ASP7 spin system and another new spin system assigned GLN7 are shown. The chemical shift values ​​correspond to... Figures 3A-3B The nuclear magnetic resonance data shown in the image.

[0180]

[0181]

[0182]

[0183] A GLY6 spin system with an HN chemical shift of 7.71 has also been assigned ( Figure 3AThe presence of a nuclear Oferhausen effect (NOE) between the Hα of this spin system and the HN of GLN7 supports the 7th position of GLN. Identification by nuclear magnetic resonance (NMR) is challenging due to the low concentrations of GLN7 and GLU7 variants, their weak proton chemical shift signals, and overlap with those of more abundant variants. The GLU7 spin system has not yet been assigned, but high-resolution mass spectrometry (HRMS) data and chemical modifications support the presence of the GLU7 variant. TOCSY and NOESY analyses were also used to assign spin systems corresponding to previously characterized amino acids in cytosine. Some unassigned spin systems were found in the TOCSY data, which may correspond to solvent, purification contaminants, or very small amounts of cytosine variants. HSQC data were used to help assign the proton chemical shifts of the NAA2 side chain and xylose glycosyl group.

[0184] The cyproterone acetate (from the same batch used in the NMR analysis) was subjected to an EDC-mediated condensation reaction with methylamine to generate OCF-S3 and OCF-S4. Figures 4A-4B (Table 4). The TOCSY fingerprint area shows the disappearance of the ASP7 spin system. Figure 4A (Table 3). The EDC condensation reaction with methylamine was the most efficient of all reactions, and mass spectrometry (MS) data showed that all OCF-I / OCF-J were converted to OCF-S3 / OCF-S4. This corresponds to the disappearance of the ASP7 spin system. A new spin system with HN of 8.40 appears and slightly overlaps with another spin system assigned to ASN7 ( Figure 4A (Table 3). Two ASN7 spin systems and a GLN7 spin system were observed in TOCSY, indicating that they were not altered by the EDC condensation reaction. This new spin system was assigned to ASP7 modified with a terminal N-methylamide. The proton chemical shifts of Hα and Hβ of the N-methylamide on ASP7 are similar to those of ASP7 because this part of the amino acid remains unchanged. Nuclear Overhauser effect (NOE) was observed between the Hα and Hβ of the N-methylamide 7 spin system and the HN of SER8, and between the Hα of Gly6 and the HN of the ASP spin system. Figure 4B The nuclear Oferhauser effect (NOE) was observed between Hβ and γ-NH and the C6-CH3 terminal methyl group. The terminal methylamide exhibits two spin systems with γ-NH proton chemical shifts of 7.87 and 7.82, and C6-CH3 proton chemical shifts of 2.56 for both. HSQC NMR showed a C13 chemical shift of 26.11 for the CH3 group on the amide nitrogen. TOCSY data also revealed three novel spin systems in the DABA5-terminal amine. Figure 4AThis suggests that DABA5 may be involved in the formation of byproducts during the EDC condensation reaction, which requires further optimization. No significant changes were observed in the spin systems of other amino acids in this compound. HSQC data were used to help assign the proton chemical shifts of the NAA2 side chain and xylose glycosyl group.

[0185] Table 3. Proton chemical shifts of OCF-S3 and OCF-S4 samples generated by coupling OCF-I and OCF-J with methylamine via EDC ( Figure 5A The ASP7 spin system no longer exists. A spin system belonging to N-methylamide ASP7 exists, where ASP7 is modified via an EDC condensation reaction with methylamine. A proton chemical shift of 2.56 ppm was observed, corresponding to the terminal carbon of the side chain. The chemical shift value corresponds to... Figures 4A-4B The nuclear magnetic resonance data shown in the image.

[0186]

[0187]

[0188] High-resolution mass spectrometry analysis of cytosine revealed mass numbers corresponding to those of OCF-K / OCF-L (containing glutamine (GLN)) or OCF-M / OCF-N (GLU) as the 7th residue (Table 4). During HPLC purification, OCF-K / OCF-L co-eluted with OCF-A / OCF-B, while OCF-M / OCF-N co-eluted with OCF-I / OCF-J. Compared to asparagine and aspartic acid, glutamine and glutamate have one more carbon atom in their side chains. Given the structural similarity of the 7th residue amino acid in these variants, the non-ribosomal peptide synthase (OcfD) responsible for adding this residue may be able to accommodate these structurally related amino acids. Non-ribosomal peptide synthases may exhibit non-specific but preferential binding to specific amino acids. OcfD may preferentially bind to asparagine, but may also bind to aspartic acid, glutamine, or glutamate. NMR analysis of the thioesterase ocfN mutant revealed the absence of ASP7, GLN7, and GLU7 variants. Studies show that OcfN can recognize ASN1 to generate OCF-A, but it may also recognize ASP7, GLN7, or GLU7 to generate other variants.

[0189] Table 4: Natural scutellarin variants identified by high-resolution mass spectrometry (HRMS), including their described and predicted elemental compositions. The description predicts the structure of the variants and is supported by chemical modifications, nuclear magnetic resonance (NMR), and high-resolution mass spectrometry (HRMS).

[0190]

[0191]

[0192] Table 5: Semi-synthetic fentanyl analogs prepared using OCF-I and OCF-J variants, including their descriptions, theoretical masses, and observed masses from MALDI-TOF or ESI-MS. Theoretical masses correspond to the predicted protonated masses. Due to the use of MALDI-TOF mass spectrometry, where the signal intensity of sodium and potassium adducts is higher than that of the protonated compounds, some theoretical masses were not observed. These semi-synthetic analogs can also be prepared by EDC coupling with OCF-M and OCF-N containing glutamic acid at position 7, but are not listed here.

[0193]

[0194]

[0195]

[0196] Example 2—Semi-synthetic analogue at the 7-position of aspartic acid

[0197] EDC condensation was performed by incubating OCF-I and OCF-J with a 10-fold molar excess of EDC, hydroxybenzotriazole (HOBt), and a selected amine in dimethylformamide (DMF) or dimethyl sulfoxide (DMSO). Figure 5A EDC condensation can also be carried out on OCF-M and OCF-N variants. Figure 5B After incubation, the reaction mixture was purified by reversed-phase high-performance liquid chromatography (RP-HPLC) as described in the Method section.

[0198] This modification itself may cause changes in retention time in reversed-phase high-performance liquid chromatography (RP-HPLC). Several primary amines have been successfully condensed in the reaction, and a secondary amine (dimethylamine) has also reacted successfully. Figure 5A The condensation reaction of benzylamine was unsuccessful, possibly due to steric hindrance caused by the benzene ring, even with increased temperature and extended reaction time. OCF-I and OCF-J could also be reconstituted into OCF-A and OCF-B via EDC-mediated condensation with ammonia. The larger amine used in the condensation reaction increases the hydrophobicity of the analogs, thus requiring a higher proportion of acetonitrile for elution in the HPLC gradient. Mass spectrometry (ESI-MS or MALDI-TOF) was used to confirm the quality of the expected analogs (Table 5). Nuclear magnetic resonance (NMR) analysis was performed on analogs OCF-S3 and OCF-S4 to confirm their structures as modified at the ASP7 position. Figures 3A-3B and Figures 4A-4BEDC condensation was also performed on OCF-A and OCF-B, which do not contain carboxylic acids, without the formation of any analogues, supporting the specificity of this chemical reaction.

[0199] The minimum inhibitory concentrations (MICs) of three indicator strains (Saccharomyces cerevisiae DGY6, Candida albicans ATCC3147, and Candida glabrata ATCC2001) were determined using the CLSIM27-A3 method. The MIC values ​​of the aspartic acid 7-position cytosine OCF-I and OCF-J were 1-2 μg / ml, and more active semi-synthetic analogs could be prepared from OCF-I and OCF-J.

[0200] OCF-S3 and OCF-S4, synthesized using methylamine via EDC condensation, exhibited MIC values ​​half that of OCF-I and OCF-J. OCF-S9 and OCF-S10, synthesized using propylamine via EDC condensation, also showed comparable MIC values. Interestingly, the MIC values ​​for EDC condensation using ethylamine were 1–2 μg / ml, comparable to OCF-I and OCF-J. A linear relationship was expected between the size of the amine used and the change in antifungal bioactivity. However, this pattern was not observed with the MIC values ​​from methylamine to propylamine, where the MIC values ​​of OCF-S7 and OCF-S8 (ethylamine) were 4–8 times higher than those of OCF-S9 and OCF-S10 (propylamine). Larger primary amines, such as dodecylamine (molecular weight = 185.35 g / mol) and undecylamine (molecular weight = 171.32 g / mol), successfully produced analogs OCF-S11 / OCF-S12 and OCF-S13 / OCF-S14. The MIC values ​​of OCF-S13 and OCF-S14 against Candida glabrata were 8 μg / ml, indicating that the modified region can accommodate a large number of structurally diverse modifications while still maintaining low-micromolar inhibitory activity (Table 6).

[0201] EDC-mediated condensation reactions of OCF-I and OCF-J with ammonia yielded OCF-A and OCF-B variants (designated OCF-S1 and OCF-S2), which convert ASP7 to ASN7 (Table 6). The inhibitory activity of the reaction mixtures of OCF-S1 and OCF-S2 was twice that of OCF-I and OCF-J, but their activity did not recover to the reported activity levels of the native variants OCF-A and OCF-B (Table 6). ESI-MS data indicated that the ammonia reaction generated OCF-A and OCF-B variants, but also produced additional products with masses of 1183.56 Da and 1998.57 Da (OCF-S15 and OCF-S16). The masses of these variants in the reaction correspond to the unwanted dehydration byproducts of OCF-I and OCF-J, designated OCF-S15 and OCF-S16. The MIC values ​​of these dehydration byproducts are higher than those of OCF-I and OCF-J, which leads to inconsistencies in the reported MIC values ​​of reaction mixtures containing OCF-S1, OCF-S2, OCF-S15 and OCF-S16 (Table 6).

[0202] Table 6. Minimum inhibitory concentrations (MICs) of natural serotonin variants and semi-synthetic serotonin analogs against *Saccharomyces cerevisiae* DGY6, *Candida albicans* ATCC3147, and *Candida glabrata* ATCC2001 in standard YPD growth medium. The MIC values ​​of OCF-I / OCF-J were higher than those of OCF-S1 / OCF-S2, OCF-S3 / OCF-S4, OCF-S5 / OCF-S6, OCF-S9 / OCF-S10, and OCF-S19 / OCF-S20. For *Saccharomyces cerevisiae* DGY6, the MIC value of OCF-I / OCF-J was equal to that of OCF-S7 / OCF-S8, but lower than that of OCF-S11 / OCF-S12, OCF-S13 / OCF-S14, and OCF-S21 / OCF-S22. ND indicates not determined. *The MIC values ​​of OCF-S1 and OCF-S2 were determined using samples containing a mixture of OCF-S1 / OCF-S2 and OCF-S15 / OCF-S16, because OCF-I and OCF-J could not be separated by chromatography after undergoing an EDC reaction with ammonia.

[0203]

[0204] The EDC condensation of the OCF-I and OCF-J variants can also be carried out using amines containing terminal functional groups for subsequent synthesis of various analogs. 3-Amino-1-propanol was chosen to prepare analogs with terminal hydroxyl groups on the ASP7 residue (OCF-S19 and OCF-S20). Even primary amines as large as dodecylamines successfully underwent condensation, indicating that the size of the amine did not interfere with the reaction. The hydroxyl group of 3-amino-1-propanol was protected by reaction with tert-butyldimethylchlorosilane (TBS) chloride; the protected compound was successfully used in the EDC condensation reaction to generate OCF-S19 and OCF-S20. These findings suggest that analogs of 3-amino-1-propanol can also undergo EDC condensation reactions with OCF-I and OCF-J. Figure 6A The MIC values ​​of OCF-S19 / OCF-S20 were tested, showing that their MIC values ​​were 2-fold lower than those of OCF-I and OCF-J (Table 6). This analogue exhibits superior activity compared to ASP7 cytosine while maintaining sub-micromolar activity, making it a viable linker for synthetic prodrug compounds. Figure 6B ).

[0205] In minimum inhibitory concentration (MIC) assays, serum supplementation can indicate the effectiveness of compounds in systemic infections. Reduced drug activity in the presence of serum is a common phenomenon due to the presence of plasma-binding proteins. Semi-synthetic analogs prepared using primary amines via EDC condensation showed a 2-8 fold increase in MIC after serum supplementation (Table 7). OCF-S19 and OCF-S20 showed a 4-8 fold increase in MIC after serum supplementation (Table 7). These values ​​are comparable to the increases in MIC in serum seen with OCF-A and OCF-B.

[0206] Table 7. Minimum inhibitory concentrations (MICs) of virucidal variants and analogs against *Saccharomyces cerevisiae* DGY6, *Candida albicans* ATCC3147, and *Candida glabrata* ATCC2001 in YPD growth medium supplemented with 20% human serum. The numbers in parentheses indicate the fold increase in MIC values ​​compared to standard YPD medium. The MIC values ​​of virucidal semi-synthetic analogs increased by 2–8 times in serum-supplemented media.

[0207]

[0208]

[0209] OCF-S19 and OCF-S20 were chosen as the final metabolites of the prodrug analogs because they exhibited potent antifungal activity in vitro. The terminal hydroxyl group will act as a linker, attaching a metabolizable prodrug functional group, which will release OCF-S19 and OCF-S20 upon metabolism. Figure 6BThe functional groups of the prodrugs studied include phosphate groups, methyl succinates, and benzoates. Current lead designs are the phosphate prodrug analogs OCF-S21 and OCF-S22, in which phosphatases remove the phosphate groups to generate OCF-S19 and OCF-S20. Figure 6C The process of removing phosphate groups from OCF-S21 and OCF-S22 to generate OCF-S19 and OCF-S20 was confirmed by MALDI-MS. Fluconazole phosphate (Fosfluconazole) is an example of a phosphate-based antifungal prodrug, which is metabolized to fluconazole by a nonspecific host alkaline phosphatase. Another phosphate-based antifungal prodrug, fosmanogepix, has recently been approved in a phase 2 clinical trial for the treatment of candidemia. The MIC of OCF-S21 and OCF-S22 was 16 μg / ml, 16 times higher than that of OCF-I and OCF-J. This significant increase in MIC values ​​was expected due to the addition of phosphate groups. The phosphate groups of OCF-S21 and OCF-S22 were removed using a nonspecific alkaline phosphatase (Quick CIP; New England Biolabs) to generate OCF-S19 and OCF-S20, and this was confirmed by MALDI-TOF MS. A coverage assay was performed using Saccharomyces cerevisiae DGY6 to determine the activity of the prodrugs. Figure 7 Inhibition zones of OCF-S19 and OCF-S20 ( Figure 7 Point A) was used as a positive control. OCF-S21 and OCF-S22 ( Figure 7 The inhibition zone at point D was smaller than that of OCF-S19 and OCF-S20. When alkaline phosphatase was added to OCF-S21 and OCF-S22 and then directly spotted onto the plate, the inhibition zone did not increase because the enzyme had not yet removed the phosphate groups. Figure 7 (Point E). After incubating the enzymes with OCF-S21 and OCF-S22 at 37°C for 90 minutes, the size of the inhibition zone was comparable to that of OCF-S19 and OCF-S20. Figure 7 (; Point F). The alkaline phosphatase reaction mixture showed no inhibitory effect on fungal growth, either directly applied to the plate or after incubation. Figure 7 (Points B and C). Incubation of OCF-S21 and OCF-S22 with the enzyme resulted in a 4-fold decrease in MIC values ​​compared to OCF-S21 and OCF-S22 alone (Table 6). This decrease in MIC values ​​indicates that the enzyme removed phosphate groups, thereby restoring antifungal activity. The MIC values ​​of OCF-S21 and OCF-S22 supplemented with alkaline phosphatase did not reach the levels of OCF-S19 and OCF-S20, which may be due to components in the culture medium or suboptimal assay conditions. The data support the hypothesis that alkaline phosphatase found in the blood activates prodrugs over time and support the use of systemic formulations of prodrugs for the treatment of systemic infections or cancer.

[0210] Phosphorylation of compounds may enhance activity and pharmacokinetic activity in the presence of serum. In vitro activity in mouse serum is important because any prodrug must first be tested in rodent or other small animal models. The alkaline phosphatases used to activate OCF-S21 and OCF-S22 to OCF-S19 and OCF-S20 have been shown to be nonspecific. This highlights that the dephosphorylation of OCF-S21 and OCF-S22 is promoted by a variety of nonspecific phosphatases.

[0211] Additional prodrugs have been designed to link the methyl succinate and benzyl succinate moieties to the terminal hydroxyl groups of OCF-S19 and OCF-S20. To produce the methyl and methyl succinate prodrugs, 3-amino-1-propanol is first linked to either methyl or benzyl succinate. Tert-butyloxycarbonyl (Boc)-protected 3-amino-1-propanol is linked to either methyl or benzyl succinate using N,N'-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP), followed by removal of the Boc group. The purified intermediate is then used in an EDC condensation reaction to produce the prodrug of fentanyl succinate. To date, modification at the 7-position of aspartic acid or glutamate has been the most suitable site for generating novel analogs of the parent molecule. EDC-mediated condensation provides an efficient method for generating a large library of semi-synthetic analogs. EDC condensation can also be used to generate a wide variety of linkers and functional groups, resulting in a diverse range of analogs. Further expansion and screening of analogues may uncover one or more analogues that are active in serum or other body fluid matrices.

[0212] The discovery of OCF-I, OCF-J, OCF-M, and OCF-N provides a friendly target for analog production. The analogs can be selectively produced via an efficient, simple, single-step reaction without the need for protection and deprotection steps. Furthermore, modification of the terminal side chain groups of these residues has no significant effect on antifungal activity (Table 6).

[0213] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and various modifications or variations that may be conceived by those skilled in the art based on these examples and embodiments should be included within the spirit and scope of this application and within the scope of the appended claims. Furthermore, any element or limitation of any invention or embodiment disclosed herein may be combined with any and / or all other elements or limitations (alone or in any combination) of any other invention or embodiment disclosed herein, and all such combinations are within the scope of this invention and are not limited thereto.

[0214] REFERENCES

[0215] 1.Lu,S.E.et al.Occidiofungin,a unique antifungal glycopeptideproduced bya strain of Burkholderia contaminans.Biochemistry 48,8312–8321(2009).

[0216] 2.Ravichandran,A.et al.A novel actin binding drug with in vivoefficacy.Antimicrob.Agents Chemother.63,1–13(2019).

[0217] 3.Ravichandran,A.et al.Formulation,Pharmacological Evaluation,andEfficacy Studies of Occidiofungin,a Novel Antifungal.Antimicrob.AgentsChemother.64,(2020).

[0218] 4.Hing,S.L.et al.Toxicological Evaluation of Occidiofungin againstMice andHuman Cancer Cell Lines.Pharmacol.&;Pharm.05,1085–1093(2014).

[0219] 5.Ma,J.et al.Novel antiparasitic activity of the antifungal leadoccidiofungin.Antimicrob.Agents Chemother.64,(2020).

[0220] 6.Gu,G.,Smith,L.,Liu,A.&Lu,S.E.Genetic and biochemical map forthebiosynthesis of occidiofungin,an antifungal produced byBurkholderiacontaminans strain MS14.Appl.Environ.Microbiol.77,6189–6198(2011).

[0221] 7.Ravichandran,A.,Gu,G.,Escano,J.,Lu,S.E.&Smith,L.The presence oftwocyclase thioesterases expands the conformational freedom of the cyclicpeptideoccidiofungin.J.Nat.Prod.76,150–156(2013).

[0222] 8.Wüthrich,K.NMR of Proteins and Nucleic Acids.336–361(1986)doi:10.1039 / 9781847555236-00336.

[0223] 9.F,D.et al.NMRPipe:a multidimensional spectral processing systembasedon UNIX pipes.J.Biomol.NMR 6,277–293(1995).

[0224] 10.Johnsona,B.A.&Blevinsb,R.A.NMRView:A computer program forthevisualization and analysis of NMR data*.J.Biomol.NMR 4,(1994).

[0225] 11.Izoré,T.et al.Structures of a non-ribosomal peptide synthetasecondensationdomain suggest the basis of substrate selectivity.Nat.Commun.2021121 12,1–14(2021).

[0226] 12.Calcott,M.J.,Owen,J.G.&Ackerley,D.F.Efficient rationalmodificationof non-ribosomal peptides by adenylation domainsubstitution.Nat.Commun.2020 111 11,1–10(2020).

[0227] 13.Tavares,M.et al.Adaptation and Survival of Burkholderia cepaciaand B.contaminans During Long-Term Incubation in Saline SolutionsContainingBenzalkonium Chloride.Front.Bioeng.Biotechnol.8,630(2020).

[0228] 14.Sass,A.M.et al.The unexpected discovery of a novel low-oxygen-activatedlocus for the anoxic persistence of Burkholderia cenocepacia.ISMEJ.7,1568(2013).

[0229] 15.Morgan,G.L.et al.Specificity of Nonribosomal Peptide Synthetasesin theBiosynthesis of the Pseudomonas virulence factor.Biochemistry 58,5249–5254(2019).

[0230] 16.Ravichandran,A.,Gu,G.,Escano,J.,Lu,S.-E.&Smith,L.The PresenceofTwo Cyclase Thioesterases Expands the Conformational Freedom of theCyclicPeptide Occidiofungin.J.Nat.Prod.76,150(2013).

[0231] 17.Bentley,A.et al.The discovery and process development of acommercialroute to the water soluble prodrug,fosfluconazole.Org.ProcessRes.Dev.6,(2002).

[0232] 18.Aoyama,T.et al.Population pharmacokinetics of fluconazoleafteradministration of fosfluconazole and fluconazole in critically illpatients.J.Clin.Pharm.Ther.37,(2012).

[0233] 19.Pappas,P.et al.147.Clinical Safety and Efficacy of NovelAntifungal,Fosmanogepix,in the Treatment of Candidemia:Results from a Phase 2Proof ofConcept Trial.Open Forum Infect.Dis.7,(2020).

Claims

1. A cytosine analogue, said cytosine analogue having formula (I), formula (II), formula (III) or formula (IV): Formula (I) Where R 1 For H or OH, R 2 It is H or CH3, and R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3, terminal alkyne group, terminal hydroxyl group, terminal hydroxyl group attached to a prodrug functional group, prodrug functional group or antibody; Equation (II): Where R 1 For H or OH, R 2 It is H or CH3, and R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3, terminal alkyne group, terminal hydroxyl group, terminal hydroxyl group attached to a prodrug functional group, prodrug functional group or antibody; Equation (III): Where R 1 It is H or OH, and Z is an ester, thioester, acid anhydride, acyl chloride, amide or carboxylate ion; Formula (IV): Where R 1 Z is H or OH, and Z is an ester, thioester, acid anhydride, acyl chloride, amide, or carboxylate ion.

2. The cytosine analog according to claim 1, wherein the cytosine analog is according to formula (I) or formula (II): Formula (I) Where R 1 For H or OH, R 2 For H, R 3 The possible values ​​are H, CH3, CH2CH3, CH2 CH2 CH3, (CH2). 10 CH3, (CH2) 11 CH3 or CH2CH2CCH; or R in it 1 For H or OH, R 2 CH3, R 3 It is CH3; Equation (II) Where R 1 For H or OH, R 2 Let H be the number of 'R', and R be the number of 'R'. 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3, (CH2) 11 CH3 or CH2CH2CCH; or R in it 1 For H or OH, R 2 It is CH3, and R 3 It is CH3.

3. The cytosine analogue as claimed in claim 1, wherein the cytosine analogue has formula (V) or formula (VI): Formula (V) Where R 1 It is H or OH, and R 2 For prodrug functional groups; Formula (VI) Where R 1 It is H or OH, and R 2 It is a prodrug functional group.

4. The cytosine analogue according to claim 1 or 3, wherein the prodrug functional group is a phosphate group, a methyl succinate, an ether, or a benzoate.

5. The cytosine analog according to claim 3, wherein the cytosine analog is according to formula (VII) or formula (VIII): Equation (VII) Where R 1 It is H or OH; Formula (VIII) Where R 1 It can be H or OH.

6. A pharmaceutical composition comprising a cytosine analogue according to any one of the preceding claims and a pharmaceutically acceptable carrier.

7. A method for treating or preventing fungal infections, the method comprising administering to a subject in need an effective amount of a fungicide analogue according to any one of claims 1 to 5, or an effective amount of a pharmaceutical composition according to claim 6.

8. The method of claim 7, wherein the method comprises administering the cytomegalovirus analog or the pharmaceutical composition vaginally, intramuscularly, subcutaneously, intrathecally, intravenously, or intraperitoneally.

9. The method according to claim 7 or 8, wherein the fungal infection is caused by Candida, Yeast, Trichophyton, Rhizopus, Mucor, Fusarium, Aspergillus or Cryptococcus.

10. The method according to claim 9, wherein the Candida genus is Candida albicans, Candida glabrata, Candida krusei, Candida auris, Candida parapsilosis, or Candida tropicalis.

11. A method for treating or preventing parasitic infection, the method comprising administering to a subject in need an effective amount of a cytosine analogue according to any one of claims 1 to 5, or an effective amount of a pharmaceutical composition according to claim 6.

12. The method of claim 11, wherein the method comprises administering the cytomegalovirus analogue or the pharmaceutical composition vaginally, intramuscularly, subcutaneously, intrathecally, intravenously, or intraperitoneally.

13. The method according to claim 11 or 12, wherein the parasitic infection is caused by Cryptosporidium.

14. A method for treating or preventing cancer, the method comprising administering to a subject in need an effective amount of a cytosine analogue according to any one of claims 1 to 5, or an effective amount of a pharmaceutical composition according to claim 6.

15. The method of claim 14, wherein the method comprises administering the cytomegalovirus analogue or the pharmaceutical composition vaginally, intramuscularly, subcutaneously, intrathecally, intravenously, or intraperitoneally.

16. A method for producing a cytosine analog of formula (I) or formula (II), said method comprising, in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride EDC, condensing the cytosine analog of formula (IX) or formula (X) with an amine: Formula (I) Where R 1 For H or OH, R 2 It is H or CH3, and R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3, terminal alkyne group, terminal hydroxyl group, terminal hydroxyl group attached to a prodrug functional group, prodrug functional group or antibody; Formula (IX) Where R 1 It is H or OH, and R 2 It can be NH2 or OH; Equation (II) Where R 1 For H or OH, R 2 It is H or CH3, and R 3 For H, CH3, CH2CH3, CH2CH2CH3, (CH2) 10 CH3 or (CH2) 11 CH3, terminal alkyne group, terminal hydroxyl group, terminal hydroxyl group attached to a prodrug functional group, prodrug functional group or antibody; Formula (X) Where R 1 It is H or OH, and R 2 It can be NH2 or OH.

17. The method of claim 16, wherein the amine is ammonia, methylamine, dimethylamine, ethylamine, propylamine, undecylamine, dodecylamine, but-3-yn-1-amine, 3-amino-1-propanol, protected 3-amino-1-propanol, 3-amino-1-propanol conjugated with methyl succinate, 3-amino-1-propanol conjugated with benzyl succinate, or 3-amino-1-propanol conjugated with a phosphate group.

18. The method according to claim 16, further comprising adding 1-hydroxybenzotriazole HOBt to the cytosine analog of formula (III), the EDC and the amine.

19. The method of claim 16, wherein the condensation reaction is carried out in N,N-dimethylformamide or dimethyl sulfoxide.

20. A method for producing a serotonin analog of formula (V) or (VI), the method comprising, under EDC-mediated condensation, condensing a serotonin analog of formula (IX) or (X) with an amine containing a prodrug functional group to produce a serotonin containing a terminal hydroxyl arm: Formula (V) Where R 1 It is H or OH, and R 2 For prodrug functional groups; Formula (VI) Where R 1 It is H or OH, and R 2 For prodrug functional groups; formula (IX) Where R 1 It is H or OH, and R 2 It can be NH2 or OH; Formula (X) Where R 1 It is H or OH, and R 2 It can be NH2 or OH.

21. The method of claim 20, wherein the prodrug functional group is a phosphate group, a methyl succinate, or a benzyl succinate.

22. The method of claim 20, wherein the amine is 3-amino-1-propanol, protected 3-amino-1-propanol, 3-amino-1-propanol conjugated with methyl succinate, or 3-amino-1-propanol conjugated with benzyl succinate.

23. The method according to claim 20, further comprising adding 1-hydroxybenzotriazole HOBt to the cytosine analog of formula (III), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, and the amine containing a prodrug functional group.

24. The method of claim 20, wherein the condensation reaction is carried out in N,N-dimethylformamide or dimethyl sulfoxide.

25. The method according to claim 16 or 20, wherein formula (IX) is based on the following formula: Formula (IX) Where R 1 It is H or OH, and R 2 It is OH.

26. The method according to claim 16 or 20, wherein formula (X) is based on the following formula: Formula (X) Where R 1 It is H or OH, and R 2 It is OH.

Citation Information

Patent Citations

  • Cosmetic applicator useful for skin moisturizing

    US4559157A

  • Method for producing a non greasy protective and emollient film on the skin

    US4608392A

  • Skin protective composition

    US4820508A

  • Treatment of damaged bone marrow and dosage units therefor

    US4938949A

  • Antiinflammatory skin moisturizing composition and method of preparing same

    US4992478A